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ABSTRACT 
BACKGROUND: In patients with kidney failure requiring hemodialysis (HD) treatment, intradialytic 
exercise (IDEX, exercise during HD treatment) has been advocated for its feasibility and effectiveness 
for improving important health outcomes. However, IDEX as an adjunct therapeutic strategy is 
infrequently implemented, in part due to potential risks of IDEX. 
PURPOSE: The purpose of this study was to evaluate the safety of IDEX by examining its effect on 
intradialytic cardiovascular (CV) hemodynamics.  
METHODS: Intradialytic changes in brachial, aortic and cardiac hemodynamics and autonomic 
function were examined during a normal HD session without exercise, or when 30-minutes of cycling 
exercise was performed during the 1st- or 3rd-hour into HD in 12 HD patients.  
RESULTS: IDEX performed during either the 1st- or 3rd- hour does not appear to exacerbate 
hemodynamic instability during HD. While there were transient increases in stroke volume, cardiac 
output and heart rate during IDEX, the intradialytic changes in brachial and aortic blood pressure (BP) 
parameters, cardiac hemodynamics and autonomic function were similar on days with and without 
IDEX. This null effect of IDEX on hemodynamic parameters during HD was demonstrated regardless of 
the timing of exercise and patients’ underlying CV characteristics. Patient hydration status was 
correlated with the magnitude of BP drop and autonomic dysfunction, and increasing sympathetic 
activity was also correlated with drops in BP during HD. 
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CONCLUSION: These results indicate that IDEX does not exacerbate hemodynamic instability during 
HD regardless of hydration status and the timing of the exercise. We also observed the potential roles of 
overhydration and autonomic dysfunction on hemodynamic regulation during HD. These results should 
help to improve our understanding regarding the CV safety of IDEX. 
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CHAPTER 1 
INTRODUCTION 
 
In patients with kidney failure requiring hemodialysis (HD) treatment, intradialytic exercise 
(IDEX, exercise during HD treatment) has been advocated for its feasibility and effectiveness for 
improving cardiovascular (CV) function, physical function and quality of life1-3. Despite 
promising preliminary evidence, IDEX as an adjunct therapeutic strategy is infrequently 
implemented and remains a poorly adopted area of practice, in part due to concerns many 
nephrologists have about the potential risks of IDEX4, 5. However, there is a lack of knowledge 
about what factors influence the safety of IDEX.  
A primary concern with IDEX is its potential impact on hemodynamic variables during 
treatment. Hemodynamic instability is a perpetual problem for HD patients due to the significant 
volume of fluid (typically 2-5 L) that needs to be removed by ultracentrifugation during each 
dialysis session. Volume overload (VO) is very common in HD patients, mainly due to 
uncontrolled fluid intake and a high salt diet that stimulates thirst6, as well as inadequate fluid 
removal during HD treatment. Chronic VO is associated with adverse clinical outcomes and is an 
independent determinant of mortality in HD patients7, 8. In patients with VO, the high target 
volume for fluid removal often exceeds the entire plasma volume pool, which in many cases 
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results in CV complications such as hypotensive episodes, especially in the last hour (3rd~4th) of 
HD treatment. Together with the delayed plasma refilling, inadequate CV compensation is 
suggested to be the main cause of adverse CV events during HD treatment. These events may 
lead to a vicious cycle of inadequate fluid removal during HD, subsequent fluid overload 
between HD sessions, and chronic cardiac and arterial impairment. Each of these are strong 
contributing factors for intra- and inter-dialytic CV complications.    
Although IDEX may be considered an additional CV stress during HD, it also may help 
control HD-induced hemodynamic instability, especially intradialytic hypotension. This may be 
due to exercise-induced increases in cardiac output resulting from a variety of factors, including 
increased heart rate9, increased myocardial contractility10, elevated respiration rate11, reduced 
afterload due to decreased total peripheral resistance, greater muscle pump-induced venous 
return12 and shunting of blood flow from visceral organs13, all of which combine to increase 
central blood flow.  
By contrast, some patients experience a paradoxical increase in blood pressure (BP) during 
their treatment, known as intradialytic hypertension. Underlying causes of intradialytic 
hypertension are hypothesized to be hyperactivity of sympathetic outflow14 and impaired 
vasodilatory capacity15-17. While it is possible that IDEX could exacerbate this problem, there is 
little evidence in the literature of adverse events caused by IDEX4, 18. Instead, intradialytic 
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hypertension could be attenuated after a bout of moderate intensity IDEX through the well-
known phenomenon known as post exercise hypotension. Post exercise hypotension is 
characterized by reduced sympathetic activity, increased parasympathetic activity and decreased 
vascular responsiveness to elevated sympathetic outflow that persist up to 12 hours upon 
completion of exercise19, 20. Through this mechanism, IDEX could help compensate for the 
paradoxical increase in BP during HD.  
To date, few studies have evaluated potential safety concerns of IDEX21. In particular, there 
is little data examining if: 1) a patient’s hydration status impacts their hemodynamic response to 
exercise during treatment; 2) the hemodynamic response to exercise differs in patients prone to 
either intradialytic hypertension or hypotension; or 3) the timing of the exercise during HD (e.g., 
1st vs 3rd hour) impacts the CV response during treatment. Providing more robust evidence for 
the safety and effectiveness of IDEX in patients with different hemodynamic characteristics, as 
well as evaluating the impact of exercising early vs late in the treatment, could help improve 
adoption of exercise training as a standard practice in HD clinics.  
Thus, this study was performed to explore the safety of IDEX related to CV regulation in 
HD patients. Specifically, we examined the effects and timing of IDEX on BP changes during 
HD. and determined if patients with chronic over-hydration or under-hydration have an altered 
BP response to IDEX. We hypothesized that IDEX will not exacerbate hemodynamic instability 
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during HD in all patients, regardless of their underling CV characteristics or the timing of the 
exercise. We also examined potential mechanisms underlying the intradialytic BP responses to 
IDEX.   
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
 
2-1. High prevalence of ESRD and High CV morbidity and mortality in HD patients 
The prevalence of end-stage renal disease (ESRD) has continuously increased over the last 
several decades. According to United State Renal Data System, there are currently about 640,000 
ESRD patients in the U.S., with Medicare related expenditures for their treatment reaching $28.7 
billion22. The majority of patients with ESRD (~90%) receive HD treatment as a renal 
replacement therapy in the U.S. in 201223. The all-cause mortality rates adjusted for age, race 
and gender are seven- to eight-fold greater than the general population, and CV complications 
are responsible for more than the half of deaths in HD patients24-26. The contributing factors for 
the high prevalence of cardiovascular disease (CVD) and mortality include: 1) underlying causes 
of ESRD such as diabetes mellitus and hypertension; 2) pathophysiologic abnormalities 
secondary to ESRD such as anemia, hyperparathyroidism, mineral disorders, cardiac dilation, 
and muscle wasting; and 3) HD treatment-driven acute CV disturbances and inflammation27. 
Despite advances in both HD techniques and pharmacological therapies to treat  co-morbidities, 
morbidity and mortality in this population remain extremely high25. This suggests additional 
therapeutic strategies are needed to improve the health and quality of life in HD patients.  
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2-2. CV Response and CV Complications during HD - Hemodynamic Instability  
2-2-1. Normal CV response to HD 
Excess fluid gained between HD sessions is removed through ultrafiltration during HD 
treatment. As a result of the plasma volume reduction, venous return and systemic peripheral 
vascular resistance are reduced, which causes decreases in stroke volume, cardiac output and 
mean arterial BP28, 29. Neurohumoral compensatory responses are critical in order to maintain 
central BP in the normal range, and thus, protect essential organs from ischemic insults. In 
response to progressive plasma volume loss, sensory signals from peripheral afferents are 
integrated in the central commend which initiates activation of sympathetic activity and a 
withdrawal of parasympathetic activity. As a consequence, heart rate and myocardial 
contractility increase which proportionally elevates cardiac output. In the vasculature, 
sympathoexcitation-driven vasoconstriction promotes plasma redistribution from the splanchnic 
and cutaneous circulation and thus increases central blood flow. Constriction of arterioles 
increases afterload and attenuates cardiac empting and may facilitate plasma refilling by 
lowering capillary pressure (See Figure 1). With any impairment in the CV compensatory 
mechanisms, CV complications including intradialytic hypotension and intradialytic 
hypertension can occur during a HD session. Impairment in baroreflex sensitivity, peripheral 
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vasopressor response, cardiac contractility, venous compliance and vascular perfusion capability, 
and delayed plasma refilling can each contribute to the risk of CV complications during HD 
treatment.  
 
Figure 1. Normal hemodynamic response to HD treatment and CV compensatory response  
HD: hemodialysis, BV: blood volume, SV: stroke volume, CO: cardiac output, SVR: systemic 
vascular resistance, CV: cardiovascular, BP: blood pressure  
 
 
2-2-2. Intradialytic Hypotension (IDH) 
Hypotension is the most common intradialytic complication, occurring in up to 30% of HD 
sessions30. When physical symptoms such as cramping present along with a reduction in BP, HD 
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treatment is often interrupted by stopping or slowing ultrafiltration, administration of saline, 
decreasing blood flow rate, or repositioning body posture, and this can have significant 
consequences. Reductions in ultrafiltration lead to incomplete removal of wastes and fluid during 
HD, while saline administration increases thirst, and thus fluid intake and accumulation. 
Furthermore, IDH increases the risk of further CV complications as a result of ischemic insult on 
the cerebral, mesenteric and coronary circulation, and is an independent risk factor for mortality 
in HD patients31. The main cause of intradialytic hypotension is an inadequate CV compensatory 
response to the plasma volume reduction. This includes a failure to increase heart rate, 
myocardial contractility and sympathetic nervous activity, inappropriate plasma refilling and 
peripheral vasoconstriction in response to progressive hypovolemia32. Although HD patients 
have elevated sympathetic activity at rest33, 34, vaso-pressor response was found to be impaired 
by reduced function of renal afferent nerve endings and decreased alpha-adrenoreceptor 
density35, 36. This blunted pressor response, in turn, was suggested to increase the risk of IDH. In 
addition, sudden withdrawal of sympathetic activity has been reported in response to progressive 
plasma volume reduction during HD37, 38. This may occur partly due to cardiac depressor reflex. 
The mismatch between myocardial blood volume (gradually decreasing) and vigorous contractile 
force may activate cardiac mechanoreceptors and deactivate baroreceptors via vagal afferents. 
Patients with frequent IDH episodes have been shown to have impaired cardiac function39, 
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decreased sympathetic tone40, 41, increased arterial stiffness42, impaired baroreflex sensitivity43 
and increased endotoxin 44 and systemic inflammation42. Although there is no definitive therapy 
to treat IDH, blood volume monitoring, vasoconstricting drugs, modification of dialysate 
composition and temperature, and adjustment of ultrafiltration rate and amount have been 
suggested to lower the development of IDH30, 45-47. However, blood volume monitoring has 
shown inconsistent benefits48. Vasoactive therapies such as selective α-1 adrenergic agonist 
midodrine and vasopressin have yielded effective results in some patients45, 49. However, 
increased total peripheral resistance reduces uremic toxin removal rate by decreasing capillary 
perfusion capacity, which raises a concern of decreased HD efficiency with the use of 
vasoconstricting agents. Moreover, HD prescription modification requires a high degree of 
clinical judgement and clinician involvement, which may limit its universal application in most 
HD clinics.              
2-2-3. Intradialytic hypertension (IDHTN)   
Paradoxical increases in BP during and immediately after a HD sessions, called intradialytic 
hypertension (IDHTN), occurs in 15~30% of HD sessions 50. IDHTN is associated with 
increased risk of adverse outcomes including hospitalization and mortality in HD patients51, 52. 
The potential underlying mechanisms include: 1) traditional risk factors for hypertension that 
promote increases in peripheral vascular resistance such as hyperactivity of renin-angiotensin 
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aldosterone system, sympathetic over-activity, and endothelial dysfunction; and 2) ESRD-
specific factors such as volume overload, volume-driven cardiac dilation and removal/filtration 
of anti-hypertensive medications during HD sessions50, 53, 54. Patients with IDHTN typically have 
increased sympathetic activity and reduced baroreceptor sensitivity14, increased endothelin-1(a 
potent vasoconstrictor) and decreased nitric oxide levels15-17. Recently, Inrig et al., demonstrated 
that circulating levels of endothelial progenitor cells measured at the beginning of HD was 
severely decreased, and flow mediated vasodilatory capacity is also decreased.  This indicates a 
reduced repair capacity for endothelial cells, and inadequate response to sheer stress, 
respectively, in patients with IDHTN55. Development of IDHTN was also associated with arterial 
stiffness56 and VO50, 53. 
  
2-3. Intradialytic Exercise (IDEX): Health Benefits of IDEX  
2-3-1. Decreased Physical Function and Inactivity  
Accumulating evidence suggests that HD patients experience severely reduced physical 
functioning, which is associated with a poor prognosis and impaired QOL57. Exercise capacity 
has been shown to be approximately 50% of the level in healthy sedentary controls (ranging in 
15.0 ~21.0 ml/kg/min of peak oxygen uptake)58. This is even lower than other clinical 
populations with co-existing medical problems such as severe anemia and diabetes mellitus, and 
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similar to values in heart failure patients59, 60. Patients with a VO2peak above a median value of 
17.5ml/kg/min had 17% lower mortality rates than those below the median value after 3-years 
follow-up57. The marked reduction in functional fitness observed in HD patients is attributed to 
ESRD-driven health problems including anemia, metabolic disturbances, cardiac and arterial 
dysfunction, abnormal muscle metabolism, muscle wasting, malnutrition and inflammation2, 58, 
61-63. In addition, a sedentary lifestyle is common and leads to progressive physical 
deconditioning in HD patients64. Physical deconditioning is associated with many skeletal 
muscular abnormalities and reduced cardiorespiratory function in HD patients63. Finally, self-
reported sedentarism (those who never or almost never participate in physical activity during 
leisure time) in HD patients was associated with a 62% greater risk of mortality over 1 year 
compared to nonsedentary HD patients59. Similarly, engagement in regular physical activity (2~3 
or 4~5 times/week) was associated with a 30% lower relative risk of mortality than compared to 
sedentary groups (>1time /week)65 . Thus, any increment of physical activity is likely to be 
beneficial by potentially delaying of reversing physiological deconditioning imposed by either 
ESRD and/or inactivity.   
2-3-2. Interdialytic vs Intradialytic exercise (IDEX) 
Two types of exercise, in regard to timing of exercise, have been tried in HD patients; 
exercise outside of the HD clinic (interdialytic exercise) and exercise during HD treatment 
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(intradialytic exercise, IDEX). Interdialytic exercise has been generally performed in outpatient 
settings such as rehabilitation centers with targeted outcomes such as physical function, CV 
fitness, and disease-specific risk factors2, 66. While it allows various types and intensity of 
exercise for maximal benefits, low compliance and high drop-out rate have been noted from 
previous studies. Kouidi compared the two types (inter- vs intra-dialytic) of exercise programs 
and found that the magnitude of increase in aerobic capacity was greater in interdialytic exercise 
group, partly due to the higher exercise intensities achieved, but the adherence was poorer 
compared to IDEX training67, 68. IDEX has been advocated for its feasibility, time-efficiency and 
on-site supervision of medical staff. The convenience of not having to schedule additional visits 
might be particularly attractive to HD patients who already have a high burden of time 
commitments for regular HD treatment (3~5 hours/treatment, 3 times/wk). This extensive HD 
treatment time also represents a forced sedentary period when patients are in a hypercatabolic 
state due to the acute effects of the HD on systemic inflammation, as well as the loss of 
substantial amino acids caused by the dialysis filtration process. Thus, routine IDEX is not only a 
chance to increase physical activity levels but also may offset some of the unfavorable acute 
effects of HD treatment. While modest, the numerous health benefits of IDEX training has been 
shown for the last three decades1-3. By 2014, 24 randomized control trials of IDEX in HD 
patients had been conducted with 13 aerobic exercise, 7 resistance exercise and 4 combined 
13 
 
exercise trials18. The most popular form of IDEX has been aerobic cycling using an ergometer 
placed in front of the treatment chair. This has generally been done at a mild to moderate 
intensity, based on either RPE or maximal exercise testing. The duration of exercise typically 
varies from 15 – 45 minutes, though some studies have utilized exercise protocols ranging in 
duration between 1 to 4 hours.18.   
2-3-3. Benefits of IDEX on Physical Function 
IDEX training has resulted in significant improvement in aerobic exercise capacity as 
measured by VO2peak in randomized controlled studies in HD patients69-73. The magnitude of 
improvement on VO2peak was greater with the combination of aerobic and resistance exercise 
than aerobic training alone, and also when the duration of training exceeded 6 months18. Exercise 
training also improved many indicators of physical functioning such as muscle strength74, 75, 6-
min walk test92, 93, habitual and fastest gait speed, and performance on the sit-and-stand test64, 76.   
An interesting finding regarding the anabolic effect of exercise training in HD patients was 
that 9 weeks of aerobic IDEX training resulted in improvement in muscle strength and power, in 
addition to an increase in VO2peak levels77. These improvements in strength and power were 
seen despite the fact that the aerobic training was designed to improve cardiorespiratory fitness, 
and not strength.  This somewhat unexpected benefit may have been due to the very severe 
physical deconditioning in HD patients.  
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Although this evidence suggests exercise training is feasible and is able to produce similar 
physiological changes seen in other clinical populations, the data should be interpreted with 
caution because of the selective inclusion criteria, small sample sizes, and lack of control groups 
in many of these studies. In particular, the subjects studied were generally highly functioning 
patients free of serious CV complications, which may limit extrapolating these results to the 
general HD population.  
Furthermore, anabolic effects of exercise training have not been consistently demonstrated in HD 
patients. Although the number of randomized control trials lacks limiting the power to draw 
strong conclusion, several randomized controlled trials including both inter- and intra-dialytic 
exercise studies suggest that it is difficult to increase lean mass or muscle strength by exercise 
alone. Kouidi reported increases in fiber cross sectional area (CSA), capillary and mitochondrial 
density and VO2peak after a 6 months of combination of intense strength and aerobic exercise 
training on non-dialysis days2. However, other studies that did not reach either/both high 
intensity or volume of exercise demonstrated limited anabolic benefits of exercise training. 
Johansen investigated effects of either/both resistance interdialytic exercise and nandrolone, an 
anabolic steroid and found that quadriceps CSA was increased in the exercise groups combined 
with either placebo or nandrolone injections but improvement in whole body lean mass was only 
seen in the nandrolone group78. The PEAK study, a randomized control trial of resistance IDEX 
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training, reported significant improvements in muscle quality and strength but no improvement 
in thigh muscle CSA74. The factors leading to resistance to exercise-driven changes may include 
uremia-driven abnormalities in muscle metabolism and severe physical deconditioning that limits 
application of high intensity exercise. In addition, some have suggested that nutrition support 
might be necessary to maximize benefits of exercise in HD patients79. This is because many HD 
patients are malnourished and in a highly catabolic state, especially during HD. This is primarily 
due to inflammation, poor nutrition intake, and the intradialytic loss of amino acids80. 
Intradialytic nutritional support has been shown to improve muscle metabolism81. Pupim 
demonstrated that cycling initiated 15 min after starting an HD session resulted in an increased 
uptake of amino acids and net muscle protein gain compared to intradialytic nutrition support 
alone82. Similar results were seen with the combination of nutrition and resistance exercise83. 
However, the combination of intradialytic supplementation and 24 week of resistance training 
failed to show improvement in lean muscle mass84. Lastly, the excess extracellular fluid tends to 
confound the measurement of true muscle size due to the fluid-dependence of body composition 
measures. 
2-3-4. CV Benefits of IDEX 
The risk of CVD is 10-30 fold greater in HD patients compared to in the general 
population25. Cardiac abnormalities such as left ventricular (LV) hypertrophy, and systolic and 
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diastolic dysfunction are present in up to 80% of HD patients85, 86. These CV abnormalities 
independently predict adverse CV events and are the strongest predictor of mortality in this 
population87, 88. Exercise training as a part of a comprehensive treatment program has been 
shown to reduce the risk of CVD events in patients with established CVD and other chronic 
disease conditions89, 90. However, much less is known about the CV effects of exercise training in 
HD patients. Toussaint et. al., carried a prospective cross-over trial to investigate the effect of 
IDEX on arterial function in 19 HD patients. Half of the patients initially underwent 3 months of 
IDEX, while the other half remained sedentary during their treatment. After a one month 
washout period, the groups crossed over, so the previous exercisers no longer cycled, and vice 
versa. While there was a trend for an improvement in pulse wave velocity (PWV), a marker of 
arterial stiffness, during the exercise periods, it was not statistically significant. However, PWV 
did get worse during the control period in one of the two groups which led to a significant 
difference between post-exercise period and post-control period groups91. On the other hand, a 
randomized control trial by Koh et al., found no significant change in PWV, pulse augmented 
pressure, BP and HR after 6 months of IDEX, despite a modest increase in performance during 
the 6min-walk test92. The very low estimated workload (~35kal/sessions) may have influenced 
the negative findings. Only one study directly measured cardiac function adaptation with IDEX 
training and found a modest improvement in LV ejection fraction in HD patients69. As for BP 
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benefits, an uncontrolled study by Anderson et. al., showed 3 months of IDEX resulted in 
reductions in 44-hour ambulatory BP (systolic BP: 138.4 mmHg +/- 19.6 to 125.7 mmHg +/- 
20.0 and diastolic BP: 83.2 mmHg +/- 10.2 vs. 74.7 mmHg +/- 9.0 at 0 and 3 months), as well as 
reductions in BP immediately before and after HD. A few randomized control trials included BP 
values as a study outcome with no reported post-intervention value71 and no change after the 
intervention75, 91, 92.  In addition, a study by Ouzouni et. al. reported a reduction in resting BP 
after 10 months of IDEX (systolic BP: 142.9 mmHg +/- 14.6 to 135.3 mmHg +/- 11.6 and 
diastolic BP: 86.8 mmHg +/- 7.8 vs. 79.2 mmHg +/- 7.7 at 0 and 10 months)93. Despite no 
significant reductions in BP after IDEX training, Painter and Miller have shown decreased use of 
antihypertensive medications72, 94.  
The paucity of exercise-related CV data might be due in part to complications associated 
with measuring CV parameters during dialysis.  In particular, the significant fluid shifts 
between and during HD sessions in HD patients complicates these analyses. Many of the well-
accepted CV clinical markers including BP, arterial compliance and myocardial contractility 
change their values depending on fluid volume status and, therefore, can be misrepresented in the 
presence of hyper-, hypo-volemia or altered cardiac geometry95. Standardization of measurement 
protocols and alternative methods with minimal fluid-dependence would help lower intra-patient 
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variability in CV measures, and allow for better characterization of exercise-induced changes in 
CV function in HD patients.  
2-3-5. Benefits of IDEX on Autonomic Function  
Abnormal autonomic regulation is frequently observed in HD patients, as generally reported 
by increased sympathetic activation96-99. Heart rate variability analysis provides information of 
cardiac autonomic modulation of heart rhythm by measuring beat-to-beat fluctuations in heart 
rate or variations in consecutive R-R intervals. Decreased heat rate variability has shown to be a 
risk factor for cardiac adverse events100 and mortality in HD patients101-104. 6-months of exercise 
training in 60 HD patients significantly increased 24-hour heart rate variability which indicates 
increased cardiac vagal activity58. 10-months of combination of cycling and strength exercise 
training also led to an improvement in heart rate variability indices69. However, 12 weeks of 
aerobic training did not result in change in heart rate variability, suggesting the potential need for 
a longer period of exercise in order to cause changes in cardiac autonomic function105. IDEX 
training also yielded a marked improvement of baroreflex activity that was associated with the 
magnitude of improvement in patient’s functional capacity.70 
2-3-6. Benefits of IDEX on HD Adequacy 
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Adequacy of HD treatment is positively correlated with hospitalizations106, 107 and 
mortality108 in HD patients. Acute bouts of IDEX have resulted in increased removal of 
unwanted solutes, indicative of enhanced HD efficacy, as evidenced by reductions in post-HD 
rebound of urea, creatine and potassium109, and increased phosphate removal110-112. Furthermore, 
compared to the usual HD care, chronic IDEX training resulted in higher HD adequacy (Kt/V) 
based on pooled analysis of 233 HD patients from 6 randomized control trails18. The underlying 
mechanisms are suggested to be increased diffusive flux in solutes from working muscles to 
blood stream109. However, the effect of IDEX on HD adequacy is inconclusive with null findings 
of urea clearance rate changes in several studies110, 111, 113. In addition to inherent high intra- and 
inter-variability of HD adequacy within patients, heterogeneity of exercise modality, equations 
and solutes used for calculation of HD efficiency, and subject inclusion criteria have been 
suggested to contribute to the conflicting results112.      
2-3-7. Psychological Benefits of IDEX 
Severely reduced quality of life has been consistently reported114, 115, and linked to poor 
morbidity and mortality in HD patients116. Functional limitations, ESRD-co-morbidities, 
extensive time-commitment to HD treatment, and a restrictive renal diet all contribute to the 
compromised quality of life in HD patients. IDEX training has resulted in favorable 
psychological adaptations in HD patients. Decreased subjective feeling of anxiety, depression, 
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fatigue and bodily pain and increased vitality has been reported in numerous studies that 
employing IDEX training64, 117, 118. Furthermore, quality of life was enhanced with improved 
perception of physical functioning, general health and mental health after an IDEX program in 
HD patients64, 76, 119, 120.     
 
2-4. Barriers to IDEX 
Given the beneficial effects of exercise training, the Kidney Disease Outcomes Quality 
Initiative (K/DOQI) clinical practice guidelines included recommendations that “all dialysis 
patients should be counseled and regularly encouraged by nephrology and dialysis staff to 
increase their level of physical activity” in Guideline 14.2 and “the goal for activity should be for 
cardiovascular exercise at a moderate intensity for 30 minutes most, if not all, days per week” in 
Guideline 14.4. Despite the strong rationales, exercise during HD as an adjunct therapeutic 
strategy in HD is infrequently implemented and remains a poorly adopted area of practice. 
However, data on the prevalence of IDEX in clinical practice, either in the U.S. or abroad, is  
very limited121 122.   
Several studies have investigated perceived-barriers to increasing physical activity in HD 
patients and suggested combined roles of disease- , patient- and health-care personnel- oriented 
factors4, 123-126. Lack of interest and motivation was found to be the biggest perceived barrier to 
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engaging in exercise, although desires to improve medical conditions were still noted in HD 
patients126. On the other hand, clinicians self-reported that medical safety concerns relating to 
uncertainty of optimal exercise modality and comorbidity screening have limited their 
encouragement of IDEX for patients4, 123. Of note, nephrologists’ perception regarding patients’ 
interest in exercise was underappreciated. While 4% of patients expressed disinterest in exercise, 
35% of nephrologists indicated patients would not be interested in exercise, and many of them 
doubt of effectiveness of exercise counseling to increase patients’ physical activity levels. 
Similarly,  safety concerns related to participating in physical activity was raised more in 
clinicians than patients (40% and 8% respectively)123. This may partly explain the deficit of 
exercise counseling by clinicians in most HD clinics4. According to reports from exercise 
intervention studies, the most common reason for dropouts and barriers for engaging in exercise 
programs was a lack of patient motivation, as opposed to health-related impairment67, 68, 126. 
Bennett sought to identify factors affecting sustainability of exercise program in HD patients. 
Inclusion of committed medical staff and dedicated exercise professionals as well as their 
encouragement during HD were found to be important components of successful continuation of 
exercise programs in the HD community127. Thus, increasing knowledge on safety aspects of 
IDEX may help facilitate exercise counseling by clinicians which could help raise patients’ 
interest and motivation to increase physical activity levels in HD patients. 
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2-5. Risk and Adverse Events with IDEX 
The risk of adverse events from participating in an exercise regime is elevated in HD 
patients given the high prevalence of ESRD-driven co-morbidities including CVD, 
hyperparathyroidism, muscle myopathy, neuropathy and bone disease. Furthermore, acute effects 
of the HD treatment itself may impact the risk for CV events during HD. HD generates 
considerable hemodynamic, electrolytic, and neuro-humoral stresses128. Specifically, HD can 
cause acute CV stress due to fluctuations in serum calcium concentrations129, sympathetic 
hyperactivity130, recurrent ischemia due to reduced coronary flow reserve131, and endothelial 
dysfunction due to increased oxidative stress132, 133. While musculoskeletal injury is a common 
concern related to exercise, the potential increased risk of a life-threatening CV events may 
dissuade HD patients and their healthcare personnel from engaging in IDEX.  
Generally, IDEX training in HD patients has been shown to be safe and well tolerated, although 
few studies have directly assessed safety concerns with IDEX. There has been no report of 
serious injuries as a result of participation in IDEX programs127, 134. Among seventeen 
randomized control trials that reported adverse events, three hypotensive events (two in the 
exercise groups and one in the control groups) and five musculoskeletal complications in the 
exercise groups were reported from three studies73-75. No overall significant effect of engaging in 
IDEX on incidences of adverse events was confirmed in a recent meta-analysis18. It should be 
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noted that study participants have been selective to relatively healthy, with low levels of 
comorbidities in general. Furthermore, the available studies were not designed to identify safety 
aspects of IDEX in HD patients. Nevertheless, cardiac rehabilitation programs historically have 
yielded minimal numbers of adverse cardiac events. The likelihood of adverse events can be 
minimized by using a progressive approach to an exercise regime, proper medical screening, and 
disease-specific considerations such as volume overload status by the medical team at the 
clinic135.   
 
2-6. Factors that May Affect Risk of CV Complications to IDEX 
2-6-1. Volume Overload (VO) Status     
One of the critical consequences of renal failure is retention of extra fluid due to the low or 
absent urine production. Removing this excess fluid is a primary purpose of each HD treatment. 
Accordingly, HD patients are exposed to frequent body fluid shifts driven by fluid removal 
during HD treatment and fluid retention between HD sessions. When inadequately treated over 
time, the excess volume raises BP in the vasculature and creates a substantial volume load to the 
heart. VO is very common in HD patients with the reported prevalence of 15~37% in HD 
patients6. However, this prevalence data was derived from quantitative assessments of intra and 
extracellular fluid volume estimated using bioimpedance analysis, which may underestimate a 
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patient’s actual volume overload. In reality, it is very difficult to precisely determine a patient’s 
true volume status. Indeed, a central tenet of nephrology practice is the belief that almost all 
patients with high BP, or who are on a BP medication to control BP, are likely to have chronic 
VO. Using this subjective criteria, more than 80% of all HD patient’s in the U.S. may have 
chronic volume overloaded.     
The high prevalence of VO is primarily due to inadequate fluid removal and uncontrolled 
fluid intake resulting from a high salt diet6. In patients with high fluid weight gain between HD 
sessions, the high target volume of fluid removal often exceeds the entire plasma volume pool, 
which in many cases results in CV complications such as hypotensive episodes, especially in the 
last hour (3~4th) of HD treatment. Together with the delayed plasma refilling, inadequate CV 
compensation is suggested to be the main cause of adverse CV events during HD treatment. This 
intolerance to HD treatment hinders complete correction of the volume gained between HD 
sessions, which subsequently contributes to development of chronic VO. VO-driven 
complications including hypertension and LV hypertrophy are highly prevalent, and likely 
contribute to the development of further CV manifestations in HD patients136 85, 86. Indeed, 
chronic VO has been shown to be associated with systemic hypertension and unfavorable arterial 
and cardiac remodeling, and is also an independent predictor of mortality in HD patients137-139.    
2-6-2. Autonomic Dysfunction 
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Chronic uremia affects autonomic control of the CV system, mainly as a result of central 
and/or peripheral uremic neuropathy140, 141. Chronically elevated SNS activity has been 
consistently reported in HD patients38, 142 and as well as in mild to moderate chronic kidney 
disease patients143-145. Furthermore, increased SNS activity is believed to be both a cause and 
consequence of uncontrolled hypertension, and is linked to the ESRD progression and the 
increased risk of mortality in HD patients38, 143, 145, 146. Although the mechanisms involved in the 
elevated sympathetic tone in kidney patients remain poorly understood, it might be driven by 
signals from diseased kidneys that chronically trigger renal afferent nerve pathways147-149. Renal 
ischemia, hypoxia, adenosine, and angiotensinΠare considered the initial signals. Other 
pathophysiologic mechanisms for elevated SNS activity include an abnormally increased chemo-
reflex and local skeletal muscle-reflex sensitivities35, baroreflex dysfunction, decreased nitric 
oxide bioavailability150, 151 and increased oxidative stress. In heart failure patients, abnormalities 
in peripheral reflex control and central neural integration at resting and during exercise are 
commonly seen152-154 , and likely contribute to exercise intolerance155. Despite limited numbers, 
several studies have tested the role of autonomic control during dynamic exercise in HD patients. 
Park et. al., observed a greater increase in BP levels with moderate intensity isometric and 
rhythmic exercise (3 min of static handgrip exercise at 30% of maximum voluntary contraction) 
from baseline levels in ESRD patients compared to age-matched controls142. This abnormally 
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increased BP was mainly driven by an increase in heart rate, which indicates an impaired 
response to central command. Further experiments demonstrated that an elevated activation of 
exercise pressor reflex (metabo- and mechano- reflex) was partly responsible for the greater 
increase in BP levels after a bout of exercise in ESRD patients156, 157. Thus, augmented 
sympathetic outflows mediated by local muscle reflexes may compromise exercise tolerance in 
HD patients by overly-excited myocardial tissues, increased peripheral resistance and altered 
redistribution of blood flow. Particularly, the latter two complications can limit oxygen supply to 
active muscles contributing to the development of myopathy. In addition, impaired baroreceptor 
sensitivity is suggested to contribute to abnormal hemodynamic responses to exercise43, although 
limited evidence exists in HD patients.  
2-6-3. Vascular Abnormalities  
HD patients have a number of vascular abnormalities characterized by accelerated vascular 
aging process, especially in the large arteries158. Markers of arterial stiffness including PWV and 
pulse pressure were positively associated with CV events and all-cause mortality88, 159. The 
potential pathophysiological vascular mechanisms in HD patients include increased intima-
medial thickness, increased arterial stiffness and endothelial dysfunction from diminished 
synthesis and bioavailability of endothelial-derived nitric oxide150, and from increased levels of 
ADMA, an inhibitor of endothelial nitric oxide synthase160, 161. The change in vascular tone has 
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an increasing role in maintaining circulatory stability when the total plasma volume and 
ventricular volume are critically low. The arterial maladaptation may predispose hemodynamic 
instability in response to exercise. These vascular abnormalities are likely to limit the efficiency 
of compensatory vaso-dilatory and vaso-constrictive capacity to stimuli such as hypovolemia and 
the concomitant exercise during HD.   
2-6-4. Cardiac Abnormalities 
HD patients have the high prevalence of cardiac structural and functional abnormalities such 
as LV hypertrophy, reduced LV contractility and compliance85, 86. These cardiac abnormalities 
increase the risk of CV complications during HD treatment, especially with concomitant 
exercise. LV hypertrophy and large artery stiffness reduce coronary flow reserve which 
consequently increases susceptibility to myocardial ischemic events during increased demand. 
The increased risk of myocardial ischemia during HD treatment has been indicated by abnormal 
echocardiogram such as ST-segment depression and elevated plasma markers of myocardial 
damage like cardiac troponin162, 163. In addition to the suboptimal blood supply to the 
myocardium, the role of cardiac dysfunction in producing abnormal exercise responses has been 
extensively studied in patients with heart failure. Exercise performance is shown to be 
compromised due to inadequate cardiac output with or without concomitant rise in ventricular 
filling pressure in cardiac patients. Heart failure patients have been shown to have decreased LV 
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contractility and blunted reductions in afterload that consequently lead to an attenuated reduction 
in end-systolic volume, and eventually a decreased cardiac output in response to exercise164 165. 
The inability of the heart to increase cardiac output to compensate for an increased metabolic 
demand during exercise leads to dyspnea (by increased LV filling pressure and impaired 
pulmonary gas exchange), decreased peripheral oxygen extraction (by impaired vasodilation), 
abnormal skeletal muscle metabolism (by increased ischemia-driven inflammation), and 
subjective symptoms of fatigue (by increased anaerobic metabolism and accumulation of lactate 
in skeletal muscle). All of these abnormal physiological responses contribute to decrease 
exercise tolerance in patients with cardiac disease. Studies showing decreased tolerance to HD 
treatment in patients with cardiac dysfunction suggest an increasing risk of CV complications 
with concomitant exercise. Van der Sande et. al., showed that HD patients with cardiac failure 
had a greater drop in BP during HD than HD patients without cardiac failure despite the same 
volume of intradialytic fluid removal166. However, no study has examined the role of the 
presence of cardiac abnormalities on hemodynamic response to IDEX in HD patients.     
 
2-7. CV Response to Exercise  
The main purposes of CV regulation during exercise are 1) to provide adequate oxygen 
supply to fulfill metabolic demand in exercising muscles and 2) to regulate systemic arterial BP 
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in order to maintain adequate perfusion pressure to vital organs167. Dynamic exercise engages 
both central and peripheral mechanisms to produce normal physiological responses for the 
increasing metabolic needs. Exercise involving large muscle mass induces metabolic 
vasodilation in skeletal muscle vasculature causing a drop in systemic vascular resistance. 
Despite the decreased vascular resistance, mean arterial BP has been shown to increase slightly 
during exercise in which autonomic control plays a critical role. Autonomic peripheral afferent 
signals from baroreflex, chemoreflex and skeletal muscle receptors are integrated at central 
command which causes augmented sympathetic nerve activity over parasympathetic nervous 
activity in the heart, adrenal gland, and the splanchnic and skeletal muscle vasculature during 
exercise. As a result, heart rate and myocardial contractility are increased as well as augmented 
venous return by muscle pumping action, which together contribute to increase cardiac output. In 
addition, sympathetic outflow causes peripheral vasoconstriction in non-exercising tissues and 
large blood vessels, which shunts blood flow to the active muscles where vasodilation has to 
occur to meet increasing oxygen needs in exercising skeletal muscles. This local vasodilation 
occurs despite an increased systemic sympathetic outflow (termed “functional sympatholoysis”) 
because the redirected blood flow increases vascular shear stress on endothelium in skeletal 
muscle tissues which causes production of nitric oxide, a vasodilator. The magnitude of 
attenuation of sympathetic constriction is greater as the intensity increases168, 169. Adjustment 
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between cardiac output by preload, afterload, heart rate, and peripheral vascular tone is a 
critically important task of CV system to maintain homeostasis of systemic BP during exercise.   
 
 
Figure 2. CV response to exercise and CV compensatory response 
SM: skeletal muscle, SM VR: skeletal muscle vascular resistance, SV: stroke volume, CO: 
cardiac output, SVR: systemic vascular resistance, CV: cardiovascular, BP: blood pressure  
 
2-8. Potential CV Mechanisms by which IDEX may Help Hemodynamic Instability  
Although exercise may act as an additive CV stress during HD, chronic exercise may help 
prevent adverse CV events during HD by improving CV function. Exercise training has shown to 
cause various favorable CV adaptations including reduced cardiac stress170 and stiffness171 172, 
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improved coronary vascular dysfunction173, baroreflex sensitivity and arterial stiffness174 in 
subjects with established CV disease.  These factors interact to improve CV compensatory 
mechanisms. Furthermore, a bout of exercise elicits a complex series of CV adjustments to meet 
increasing metabolic needs that can, in turn, ameliorate hypotensive conditions during HD. 
Exercise causes increased sympathetic activity which leads to increased cardiac output resulting 
from a variety of factors including increased heart rate9, increased myocardial contractility10 and 
elevated respiration rate11. Considering depressed sympathetic activation during progressive 
blood volume loss is one of the main mechanisms of IDH37, 38, exercise-induced-
sympathoexcitation signaled by metabolic change (by chemo reflex) and mechanical change (by 
exercise pressor reflex) may help promote adequate autonomic input to prevent ischemia. In 
addition, other neurohumoral mechanisms including reduced afterload by decreased peripheral 
resistance, redirected blood flow from the organ system13, and muscle pump-induced increased 
venous return12 combine to increase central blood flow.  
Moreover, increased venous return by non-neural pathways has been shown to be effective 
in treating hypotensive symptoms. Voluntary movements such as leg-crossing, muscle tensing, 
and foot wiggling while sitting increases BP in individuals with orthostatic hypotension175, 176. In 
HD patients, Yamamoto et al., applied an inflatable abdominal band and saw an attenuated drop 
in systolic BP of 16.7mmHg in 25 HD patients with uncontrolled orthostatic hypotension177. This 
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magnitude of improvement of systolic BP control is comparable to pharmacological therapies 
including midodrine, cool dialysis, and l-threo-3,4-dihydroxyphenylserine (which reduced the 
drop in  systolic BP 10~15mmHg)30, 46, 178, 179. The main underlying mechanism is suggested to 
be shifting blood pool from the abdominal vascular bed to the central vasculature to increase 
venous return, as evidenced by increased ejection fraction and a fall in atrial natriuretic peptide 
concentration177. 
The post exercise recovery process, driven by continued elevation of skeletal muscle 
perfusion, oxygen delivery and uptake, may help control IDHTN after a bout of IDEX. The 
phenomenon known as post exercise hypotension is characterized by reduced sympathetic 
activity, increased parasympathetic activity and decreased vascular responsiveness to elevated 
sympathetic outflow, and persists up to 12 hours upon completion of exercise19, 20. The length of 
hypotensive effect is shown to last longer in hypertensive than normotensive subjects180, 181. 
Given that the underlying causes of IDHTN include hyperactivity of sympathetic outflow14,  
impaired vasodilatory capacity by decreased nitric oxide activity15-17, and increased arterial 
stiffness55, 56, IDEX may produce compensatory CV responses that helps control  abnormal 
hemodynamic response during and after HD treatment in patients with IDHTN.  
Despite the supporting evidence for the hemodynamic benefits of exercise in other clinical 
populations, very limited information is available on hemodynamic responses to a bout of IDEX 
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in HD patients. Investigating the therapeutic value of exercise as a non-pharmacological 
approach to ameliorate hemodynamic instability during HD is important, especially considering 
the heavy usage of vasoactive medications to treat co-morbidities in many HD patients.   
   
 
Figure 3. Potential CV compensatory responses to IDEX in patients with IDH 
HD: hemodialysis, BV: blood volume, SM: skeletal muscle, SM VR: skeletal muscle vascular 
resistance, SV: stroke volume, CO: cardiac output, SVR: systemic vascular resistance, CV: 
cardiovascular, BP: blood pressure  
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2-9. Previous Studies on Acute CV Responses to IDEX and Limitation 
Currently, very little information is available regarding which factors influence the CV 
safety of IDEX, and only one study has investigated the safety aspect of CV responses to IDEX. 
8 HD patients cycled for 5 minutes at 60% of VO2 peak at every hour into HD treatment21. No 
significant effect of IDEX on CO, SV and BP were observed until 2hours into HD treatment, but 
the hemodynamic parameters dropped with exercise during the 3rd hour. The hemodynamic 
instability was driven partly by decreased heart rate despite fluid loss, which indicates blunted 
CV compensatory response. Leung et. al., reported no changes in mean arterial BP, heart rate and 
uremic clearance rates with a 30-minutes of cycling 2 hours into HD treatment113. In contrast, 
Banerjee et al., implemented transcutaneous muscle stimulation and passive cycling movement, 
with both eliciting an increase in systolic/diastolic BP from 121/64 to 125/66 and to 132/69 
mmHg, respectively, without a change in heart rate182. IDEX also resulted in normal 
physiological responses such as increased oxygen uptake and heart rate183 and decreased total 
peripheral vascular resistance and increased cardiac output184 without significant changes in 
mean arterial BP. By contrast, Dungey showed that, compared to on a non-dialysis day, BP 
levels were higher immediately after 1-hour of IDEX (112±20 vs. 125±18 mm Hg), lower 1-hour 
post exercise period (117±25 vs. 106±22 mm Hg) and not different at the end of HD session. 
However these BP fluctuation occurred without change in plasma markers of cardiac injury, 
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systemic inflammation and neutrophil degranulation185. In summary, IDEX was generally well 
tolerated, not eliciting abnormal hemodynamic responses except a possible increased risk of 
IDEX during the 3rd hour of treatment (Table 1).   
However, the previous investigations were not sufficiently powered to address the safety of 
IDEX in an appropriate way. Most studies did not include a control group, and the primary 
outcome examined in many was HD efficiency, an indicator of the amount of solutes removed 
during treatment. The current proposed study will be controlled within patients adding a normal 
HD session day to be compared with the day receiving IDEX. The impact of the timing of 
exercise (1- vs 3-hr into HD) will be examined as well. Among possible confounding factors, 
fluid overload status may have a significant impact on CV response to HD. Additionally, we will 
evaluate whether pre-existing CV complications that may predispose patients to abnormal 
hemodynamic responses during HD may also impact the response to IDEX. Therefore, it is 
important to understand how the CV system regulates hemodynamic changes in response to 
concomitant exercise during HD in patients with VO and/or different underlying CV conditions. 
The current proposed study includes measures of hydration, as well as an integrated set of CV 
measures, including functional and structural measures of heart, arteries, and autonomic 
function. Thus, the proposed study is innovative given the novel information we will obtain 
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regarding the interaction between VO status and IDEX on CV responses, and the inclusion of 
various CV measures, allowing deeper mechanistic understanding of CV physiology with IDEX.  
Table 1. Summary of Studies of Effects of Acute IDEX on Hemodynamic Parameters 
 
Authors, 
year 
Aim Sample 
Size, n 
Exercise 
modality 
 Timing 
of 
exercise 
Outcomes Main findings 
Moore 
et.al.,199
821 
Effects of acute 
IDEX on 
hemodynamic 
parameters 
8  
(6 
males, 
46.9 yr) 
Cycling 
for 5 min 
at 60% of 
VO2peak
,  
0,1-,2-,3-
hr into 
HD 
BP, SV, CO, 
TPR  
No difference 
in 
hemodynamic 
variables until 
2-hr.   
Exercise 
Intolerance at 
3-hr for 5 
patients due to 
↓HR, ↓BP, 
↓CO at rest  
Leung, 
2004113 
Effects of acute 
IDEX on HD 
efficiency  
15  
(8 
males, 
58.6 yr) 
Cycling 
for 
30min at 
moderate 
intensity 
on RPE 
2~2.5hr 
into HD  
Urea 
removal, 
post-HD 
urea 
rebound, 
HR, BP 
No difference 
in urea 
removal and 
rebound. BP, 
HR were 
maintained 
during IDEX 
Farese 
et.al., 
2008182 
Effects of acute 
transcutaneous 
muscle 
stimulation 
(TEMS), 
passive cycling 
(PC) on BP and 
HD efficiency 
10  
(6 
males, 
58.1 yr) 
15 min of 
TEMS 
and 
20min of 
passive 
cycling 
2 into 
HD  
BP, HR, 
serum urea, 
nitrogen, 
phosphorous  
Both TEMS& 
PC  ↑MBP, 
↑urea and 
phosphorous 
removal 
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IDEX: interdialytic exercise, HD: hemodialysis, BP: blood pressure, SV, stroke volume, CO, 
cardiac output, TPR: total peripheral resistance, HR: heart rate, MBP: mean arterial blood 
pressure, RBV: relative blood volume, TEMS: transcutaneous muscle stimulation, PC: passive 
cycling  
 
 
 
Table 1 (cont.)      
Authors, 
year 
Aim Sample 
Size, n 
Exercise 
modality 
Timing 
of 
exercise 
  Outcomes Main findings 
Banerjee 
et.al. 
2004184 
Effects of acute 
IDEX on the 
fall RBV 
during 
isovolaemic 
HD  
10 
(4males
, 37yr)   
Cycling 
for 
10min at 
20% 
greater 
than 
HRpre-HD  
In the 
beginnin
g HD 
before 
starting 
UF  
RBV, 
hemodynami
c parameters 
IDEX  
↓RBV, ↓TPR  
, ↑CO, ↑SV,   
Rosales 
et. al., 
1998183 
Effects of acute 
IDEX and cool 
dialysate on 
hemodynamic 
parameters 
4  
(49.9 
yr) 
Cycling 
up to 1 hr 
at 20-
25W and 
60-80 
rpm 
1hr into 
HD 
Thermal, 
hemodynami
c and energy 
expenditure 
parameters   
IDEX  
↔MBP, 
↓RBV%chang
e but reversed 
in the end of 
HD, ↑O2 
uptake/HR   
Dungey 
et. atl., 
2015185  
Effect of acute 
IDEX on   
15 ( 9 
males, 
57.9 yr) 
Cycling 
for 
30min at 
moderate 
intensity 
on RPE 
1 hr into 
HD 
BP, HR,  
cardiac 
injury 
markers, 
inflammation
, neutrophil 
degranulatio
n 
IDEX ↓ BP 
at 1-hr post 
EX. No 
difference in 
plasma 
markers of 
cardiac injury 
and 
inflammation 
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2-10. Significance  
The annual mortality rate is excessively high in patients with HD treatment, despite 
advances in HD techniques and pharmacological therapies. Only half of patients survive 3 years 
after the initiation of HD25. This indicates additional therapeutic strategies are needed in this 
population25.  
From a public policy perspective, IDEX training represents a low-cost, easy to administer 
treatment strategy that could potentially reduce the burden of CV disease, the leading cause of 
death in HD patients, and other uremic symptoms including muscle wasting, anemia and 
elevated inflammation in this population. The recent National Kidney Foundation 
recommendations include an exercise prescription186, but nephrologists rarely counsel their 
patients to increase their physical activity levels or to exercise during HD treatment, in part due 
to safety concerns4.   
The proposed study is significant because it will improve our understanding of the safety of 
CV responses to IDEX, especially in relation to VO status and the normal CV response to HD. 
Results from this study will enable nephrologists to make more informed decisions regarding the 
timing and the selection of a group of patients who should/should not be encouraged to engage in 
IDEX. Such understanding will significantly advance the field and lead to improved therapeutic 
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approaches, including exercise training, that will prevent or minimize the deleterious effect of 
renal failure, as well as the HD process itself.  
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CHAPTER 3 
PRELIMINARY DATA 
The only previous research that examined the safety of IDEX in regards to hemodynamic 
responses was a small pilot study that used 5-min of IDEX21. This timeframe is too short to draw 
robust conclusions from the data, especially given that most protocols require patients to cycle 
for 30-45 minutes per session. We are currently conducting a project examining the effects of 
IDEX training on physical function and CV disease risk factors. Furthermore, we recently 
conducted a pilot study to examine hemodynamic responses to a bout of 30min IDEX. 8 HD 
patients without CHF and COPD (4 males, 4 with diabetes, age 47±13 years) were recruited 
from a local HD clinic. Patients received each of two treatments in a random order: 1) normal 
dialysis session with no intervention and 2) 30 minutes of intradialytic cycling (RPE 11) starting 
30 minutes into dialysis. Brachial systolic blood pressure (SBP), diastolic blood pressure (DBP), 
and heart rate (HR) on the non-dialyzing arm were measured every 15 minutes using an 
automated cuff built-in to the dialyzer. We found that IDEX helped maintain BP levels from 
dropping during HD session (Figure 4-6). In addition to preliminary data from these studies, 
previous work by our lab demonstrates our experience with the proposed measurement 
techniques (Figure 7 and 8).  
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Figure 4. BP responses with IDEX in HD patients.  
In a pilot study with 8 HD patients, mean arterial BP decreased over the course of a single HD 
session (p=0.029). However, the decreased trend was blunted with 30 min of IDEX implemented 
during 1st hour during HD treatment (p>0.05). The higher initial BP values on CON day may 
partly explain the higher magnitude of BP change on CON day than the day with exercise. Based 
on mixed model of repeated measures with a random effect of patients, there were no significant 
interactions between Time and Treatment (CON vs EX) in changes in BP, heart rate and relative 
blood volume indicating a bout of IDEX during 1st hour did not cause greater hemodynamic 
fluctuation than normal intradialytic hemodynamic response to HD.  
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Figure 5. Hemodynamic responses with and without IDEX in a patient with intradialytic 
hypotension (IDH) 
Intradialytic responses of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart 
rate (HR) and relative blood volume (RBV) in a patient who had IDH (SBP <90mmHg during 
HD) on the normal HD day (CON). The fluctuation of BP responses was reduced on the day 
received a 30 min of IDEX (EX). Of note, the low initial BP values on EX day may partly 
explain the blunted BP change. The similar trends were shown in two other patients with IDH (a 
decrease in SBP >25% from the pre-HD measure) (figures not shown).  
 
 
 
Figure 6. Hemodynamic responses with and without IDEX in a patient with intradialytic 
hypertension (IDHTN) 
Intradialytic responses of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart 
rate (HR) and relative blood volume (RBV) in a patient who had IDHTN (an increase in mean 
arterial BP >15mmHg during and/or immediately after HD) on the normal HD day (CON) and 
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on the day received a 30 min of IDEX (EX). The final intradialytic BP was dropped to the initial 
BP value on the day with IDEX.  
 
 
 
Figure 7. Arterial and Cardiac Relationship to Exercise Intolerance in HD patients.  
We conducted a cross sectional analysis of CV variables and physical function in 81 HD patients 
(mean age: 55.4 yr). Walking performance was more closely associated with arterial function 
(pulse wave velocity) measures than cardiac structure (left ventricular mass) or function (ejection 
fraction) in HD patients187. 
 
 
 
              
Figure 8. Relationship between left ventricular diastolic function and physical function in 
HD patients. Subclinical LVDD (left ventricular diastolic dysfunction) was identified in 50% of 
the patients undergoing HD and had a significant impact on physical function, regardless of age 
in 86 HD patients (mean age: 52.9 yr). After adjusting for age, shuttle walk distance was longer 
in the group without LVDD than with LVDD (p=0.031)188.  
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4-1. Abstract 
Background: Cardiovascular (CV) diseases are the main cause of death in maintenance 
hemodialysis (MHD) patients. Muscle wasting and declines in physical function are common in 
MHD patients, which significantly impair their quality of life. This can result from abnormalities 
in cardiac function, which can be further worsened by physical deconditioning. Left ventricular 
diastolic function parameters were recently shown to be a better predictor of exercise capacity 
than systolic measures in patients with CV complications. Little is known about the relationship 
between cardiac function and physical function in MHD patients.   
Methods: In 82 MHD patients using echocardiography, left ventricular systolic dysfunction 
(LVSD) was assessed by ejection fraction and fractional shortening, and left ventricular diastolic 
dysfunction (LVDD) was assessed by pulse wave and tissue Doppler indices. Physical function 
was assessed by gait speed, performance on a shuttle walk test, and leg muscle strength. DXA 
was used to measure whole body lean mass (WBLM). 
Results: The prevalence of LVDD and LVSD were 48.8% and 12.2% respectively. Gait speed, 
shuttle walk time, leg strength, and WBLM% were significantly higher in the group without 
LVDD than with LVDD (p <0.05 for all). However, there was no significant difference in any 
measure of physical function or body composition between patients with and without LVSD.   
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Conclusion:  This data suggests that LVDD is more closely related to physical function and 
body composition than LVSD in MHD patients, and suggests that LVDD may be an important 
therapeutic target.   
 
Key words:  maintenance hemodialysis patients, cardiac abnormalities, diastolic dysfunction, 
physical function, body composition 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
 4-2. Introduction 
The prevalence of cardiovascular (CV) disease and CV mortality are excessively high in 
patients undergoing maintenance hemodialysis (MHD) therapy 190. Cardiac abnormalities such as 
left ventricular (LV) hypertrophy, and systolic and diastolic dysfunction are present in up to 80% 
of MHD patients 85. These cardiac abnormalities independently predict adverse cardiac events, 
and are the strongest predictor of mortality in this population 88.   
Cardiac abnormalities adversely impact physical function and also can be exacerbated by 
reduced physical function; however, the relationship between cardiac and physical function in 
MHD patients is not well established. Decrements in physical function are common in MHD 
patients and significantly impair their quality of life (QOL) 191. A variety of non-cardiac factors, 
such as decreased muscle mass 192, abnormal muscle metabolism 193, and inflammation, are 
known to contribute to low physical function in MHD patients 1. However, the evidence linking 
cardiac abnormalities and physical impairment is limited.   
LV diastolic function measures have been proposed to provide better prognostic value in 
this population because they are less sensitive to blood volume changes than systolic function 
measures 194. Furthermore, LV diastolic dysfunction (LVDD), characterized by impaired LV 
dilation, is strongly associated with poor exercise capacity in other clinical populations including 
cardiac patients 195 . While inadequate cardiac output and exertional dyspnea may contribute to 
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poor exercise capacity during LVDD, the exact mechanism is unclear 196. However, no studies to 
date have examined the relationship between LVDD and reduced physical functioning in MHD 
patients. Increasing our understanding of this relationship may help identify novel therapeutic 
approaches to improve overall health in MHD patients.  
Therefore, the purpose of this study was to evaluate 1) the prevalence of LVDD in MHD 
and 2) the relationship between LVDD and physical function in patients undergoing MHD. We 
hypothesized that LV diastolic function will be associated with declines in physical function in 
MHD patients.    
 
4-3. Research Design and Methods 
4-3-1. Study population 
Eighty two patients receiving MHD therapy were recruited from hemodialysis clinics in 
Champaign and Oak Park, IL. Patients were screened for eligibility with a health and medical 
history questionnaire. Inclusion criteria for participation in this study included the following: 1) 
>3 months of MHD treatment; 2) 30-80 years old; 3) at least 3 days of MHD treatments per 
week, and,4) medical clearance from a nephrologist to determine patient’ eligibility for the study. 
Subjects were excluded if they had chronic obstructive pulmonary disease (COPD), 
decompensated congestive heart failure (CHF), or cardiovascular surgery (e.g., coronary bypass 
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or valve replacement) in the past 6 months. All participants provided written informed consent. 
All patients were treated using bicarbonate dialysis with blood flow rates between 400 and 600 
ml/min and dialysate flow rates between 500 and 800 ml/min with treatment times between 3 
and 4 hour/session. Patient clinical information was available only from participants who 
provided a HIPPA release form. This study was approved by University of Illinois at Urbana-
Champaign and at Chicago Institutional Review Boards. 
  
4-3-2. Echocardiography 
The transthoracic echocardiographic examinations were performed using a high 
resolution ultrasound system (ProSound SSD-α7, Aloka, Japan) by two experienced 
sonographers blinded to all other data and analyzed by a single sonographer. The measurement 
sessions occurred within 24 hours after a MHD session on a non-dialysis day to minimize the 
effect of fluid overload. Two-dimensional images were obtained and analyzed according to the 
recommendations of the American Society of Echocardiography (ASE) 197. At least 3 
consecutive heartbeats in parasternal long and short axis views were acquired. LV volumes and 
LV mass were measured in M-mode. LV volume parameters were indexed by body surface area 
(BSA (m2) = 0.007184×weight(kg)0.425× height(cm)0.725). LVSD was defined as LV EF < 40% 
using the Teicholz method. Left ventricular mass index (LVMI) was calculated as 
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LVM/height2.7. Left ventricular hypertrophy (LVH) was defined as LVMI > 45 (g/m2.7) for 
females and LVMI > 50 (g/m2.7) for males. LV diastolic function was assessed by standard 
Doppler echocardiographic indices 198. LV diastolic filling patterns were assessed by placing the 
pulsed Doppler sample volume between the tips of the mitral valve leaflets. Based on the mitral 
inflow velocity curve, peak early (E) and late (A) diastolic velocities, E-wave deceleration time 
(DT), and E/A ratio were assessed. Peak early-diastolic mitral annulus velocity (E’) was 
measured using tissue Doppler imaging of mitral annulus movement. LVDD stages were graded 
according to ASE guidelines using an integrated evaluation of LV filling patterns by an 
experienced sonographer blinded to all other data 199 : 1) mild LVDD (E/A < 0.8 , E’ <8 cm/s, 
E/E’ < 8 and DT > 200ms), 2) moderate LVDD (0.8< E/A< 2,  E’ <8 , E/E’<9, and DT <200) 
and, 3) severe LVDD (E/A>2, E’<8, E/E’ >9, and DT <200). The combination of moderate and 
severe LVDD was classified as ‘advanced LVDD’.     
 
4-3-3. Shuttle Walk Test and Gait Speed Assessment 
An incremental shuttle walk test (ISWT) was conducted to estimate cardiorespiratory 
performance200. ISWT is a progressive test in which patients walk back and forth continuously 
over a 10 meter course. The walking speed is paced by a series of auditory signals for the 
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termination of the 10 meter walk. The test was terminated when the subject was unable to 
complete the 10m course before the subsequent beep.  
Normal gait speed was measured prior to the start of the ISWT while patients walked at a 
self-selected speed along a 10-meter walkway. Average gait speed was calculated based on 3 
trials.   
 
4-3-4. Muscle Strength 
Bilateral quadriceps femoris and hamstring muscle strength was evaluated using 
isokinetic testing modes.  Following dynamometer calibration, knee extension and flexion 
isokinetic peak muscle torque (Nm) was evaluated at a speed of 60 degrees per second on a 
dynamometer (Biodex Medical Systems, Shirley, NY). Peak torque was recorded for 
analysis. For all tests, participants were verbally encouraged to perform as vigorously as 
possible.     
 
4-3-5. Body Composition 
Whole body fat, lean and bone mass were measured by dual emission x-ray 
absorptiometry (DXA, Hologic QDR 4500A, Bedford, MA). Whole body lean mass (WBLM) 
and regional mineral free lean mass (LM) was calculated by subtracting the bone mineral content 
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from the LM quantity of the whole body or region of interest. Whole body bone mineral density 
(BMD) was also measured. Precision for DXA measurements of interest are 1.0 – 2.0% in our 
laboratory.   
 
4-3-6. Statistics Analysis 
Continuous data was compared using one-way analysis of variance testing. Categorical 
data were compared using χ2 tests or Fisher exact tests as appropriate. Univariate regression 
analysis was performed to identify correlates of physical performance and muscle strength. 
Significant associations indicated by univariate regression analysis were included in the 
multivariable linear regression models and tested using a stepwise method with the entry and 
removal criteria of p<0.05 and <0.10 respectively. Model 1 adjusted for basic demographic (age) 
and anthropometric (BMI) measures. Model 2 included additional adjustment for other variables 
correlated with ISWT. Model 3 and 4 were performed for the relationship between LVDD and 
leg strength. The strength of the model was expressed using adjusted R-square and p-values. 
Standardized ß coefficient (ß) was reported to assess its relative independent effect on the 
outcome variable. A p-value less than 0.05 was considered statistically significant in two-sided 
tests using SPSS 22.0 (IBM, Armonk, NY). 
53 
 
4-4. Results  
4-4-1. Subject Characteristics and Prevalence of LV Diastolic and Systolic Dysfunction   
Patient demographics are shown in Table 1. The mean dialysis vintage available from 
fifty nine patients was 42.9 ± 37.9 months. Races were African American (76.8%) and Caucasian 
(22.0%). The primary causes of ESRD were hypertension (55.7%), diabetes (29.2%), polycystic 
kidney (10.1%) and nephritis/nephropathy (5.0%). There was no difference in race and primary 
ESRD causes between groups with and without LVDD. The prevalence of LVDD was 48.7% 
(34.1% with advanced LVDD and 14.6% with mild LVDD). LVSD was identified in 10 patients 
(12.2%). 
 
4-4-2. Body composition and LVDD   
WBLM % and leg LM % were significantly lower in the group with LVDD than without 
LVDD (Table 1).   
 
4-4-3. Physical function and LVDD   
  Patients with LVDD had a significantly slower gait speed and poorer performance on the 
ISWT and leg maximal extension and flexion than the group without LVDD (Figure 1).   
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4-4-4. CV parameters and LVDD 
There was no difference in CV parameters, with the exception of E’ and E/E’, between 
groups with and without LVDD (Table 2). Due to the body size difference (BMI) between 
groups with and without LVDD, stroke volume index (SVI) and cardiac output index (COI) were 
compared.  
 
4-4-5. Predictors of Physical Performance (ISWT and Leg Strength)  
LVDD, age, BMI, WBLM% and diabetes status were each significantly correlated with 
ISWT by univariate analysis, so were included in the multivariable linear regression models. In 
Model 1, both age and LVDD, but not BMI, significantly predicted ISWT performance. In 
Model 2, age, WBLM% and diabetes status, but not LVDD and BMI, significantly predicted 
ISWT performance (Table 3). Similar relationships were found between gait speed and LVDD 
(data not shown).   
LVDD and WBLM% were significantly correlated with leg extension strength by 
univariate regression. LVDD remained significant in the multivariable Model 3 when age and 
BMI were entered together, but was not a significant predictor when WBLM was entered into the 
multivariable Model 4 (Table 3). 
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LVDD, BMI and diabetes were each significantly correlated with WBLM by univariate 
regression.  LVDD remained a significant predictor of WBLM when age and diabetes were 
entered together into a multivariable regression model (R2 =.10 and p=0.002).  
 
4-4-6. LVSD and physical function and body composition parameters   
 There was no difference in all demographic, body composition, physical function 
performance and cardiac parameters except systolic function measures (SVI, COI, EF and FS) 
between groups with and without LVSD in our study population (Table 4).  
 
4-5. Discussion  
This study examined the relationship between cardiac function, physical function and 
performance, and body composition in MHD patients without overt CHF. The primary findings 
included the following: 1) the prevalence of LVDD was significantly higher than LVSD; 2) 
physical function (gait speed) and physical performance (ISWT and leg muscle strength) were 
reduced in those with LVDD; and 3) those with LVDD had a reduced whole body and leg LM%. 
By contrast, no differences in physical function and body composition were seen in MHD 
patients with and without LVSD. Our findings suggest that LVDD is associated with declines in 
physical performance and body composition in MHD patients. To our knowledge, this is the first 
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study to analyze the relationship between LVDD, physical performance and body composition in 
MHD patients.  
  
Our echocardiographic data showed that approximately half of MHD patients had LVDD 
while the prevalence of LVSD was much lower (12%). Other studies reported a similar incidence 
of LVDD (50-75%) and LVSD (10~40 %) in MHD patients including those with CHF 201. It 
should be noted that this present study excluded patients with decompensated CHF. CHF can be 
caused by LVSD, LVDD or both, but LVSD identified by a decreased EF is commonly used as 
an  echocardiographic diagnostic for CHF 202. Moreover, a lack of diagnostic knowledge in 
diastolic CHF has challenged early and accurate diastolic CHF diagnosis 203. This may explain 
the relatively low LVSD and the high LVDD prevalence in our findings.   
LVH was identified in 83.7% of patients in our analysis, which is consistent with 
previous findings in MHD patients 204. This high LVH prevalence suggests that LV structural 
remodeling may precede development of cardiac dysfunction regardless of the presence of 
decompensated CHF in MHD patients. Indeed, LVH is known to initiate a vicious cycle of 
cardiac maladaptation in MHD patients 205. Together with accompanying interstitial fibrosis and 
myocardial ischemia, increases in LV mass contributes to impaired LV diastolic distensibility, a 
main feature of LVDD. As LVDD progresses, LV end-diastolic pressure increases as a 
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consequence of inadequate LV filling in response to a given change in blood volume. Therefore, 
patients with LVDD may suffer from CV complications due to an inability to adjust LV volume 
for a given change in pressure. This results in either 1) pulmonary congestion with an increased 
blood volume or 2) hypotension with a decreased blood volume. This has significant clinical 
implications for MHD patients who experience frequent blood volume shifts between MHD 
treatments and during a MHD treatment. Therefore, identification of LVDD would provide 
important information for therapeutic strategies to prevent adverse CV events in MHD patients. 
One interesting observation was a higher percentage of females in the LVDD group than 
in the non-LVDD group (57.5% vs 26.2% respectively, p=0.004). Although not accounted for in 
this study, hormonal factors may have contributed to the high prevalence of LVDD in female 
dialysis patients. Female MHD patients have female-hormone related symptoms and accelerated 
rates of CVD and mortality compared to the general female population 206 . Further investigation 
is needed to confirm the relationship between female hormonal abnormalities and cardiac 
dysfunction in this population.     
    
Growing evidence suggests that MHD patients experience reduced physical functioning, 
which is associated with a poor prognosis and impaired QOL 57. Exercise capacity has been 
shown to be approximately 50% of the level of healthy sedentary controls 58. Physiologically, 
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exercise capacity is affected by the efficiency of oxygen delivery (central factors) and oxygen 
utilization (peripheral factors). The peripheral contributors such as decreased muscle mass 192 
and muscle metabolism 193 have been reported in MHD patients. However, few studies have 
examined cardiac mechanisms underlying declines in physical function, and the data that exist 
mostly used LV systolic function measures that are volume dependent in MHD patients 66. 
 In this present study, patients with LVDD had significantly slower gait speed, poorer 
performance on shuttle walk test, and reduced hamstring and quadriceps strength. Regression 
analysis revealed that LVDD was an independent predictor of walking performance and muscle 
strength even after adjusting for age, but not when additionally adjusting for WBLM and 
diabetes in our study population.  
A possible pathophysiological explanation for this association is that LVDD leads to 
limited LV filling and decreased cardiac output even with preserved systolic function. 
Especially, during exercise, the failure to increase cardiac output in response to the increased 
oxygen demand may significantly limit exercise performance 207. Additionally, an increased LV 
filling pressure, a hallmark of LVDD, frequently coincides with an augmented left atrial pressure 
and consequently leads to ventilation-perfusion abnormalities. This can limit exercise capacity as 
well 196. Respiratory muscle weakness, a cause for dyspnea and tachypnea, has also been shown 
to be closely related to LVDD 208. Regarding strength, abnormal skeletal muscle metabolism, 
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including impaired mitochondrial energy transfer and ATP production have been found in heart 
failure models, and may also partially explain the strength decline in patients with LVDD 209.   
     
 In MHD patients, it has been suggested that LV diastolic performance may reflect CV 
fitness more than systolic function due to the volume dependence of LV systolic function 
measures 201. Although the contribution of LV systolic function to physical performance has 
been studied widely, recent studies reported echocardiographic LV systolic function parameters 
were poor predictors of exercise capacity in patients with mild and severe cardiac disorders 207. 
Studies demonstrated that LV diastolic function surrogates such as E’, E/E’ and left atrial 
volume were strongly associated with exercise capacity in cardiac patients 210. This present study 
found that only LVDD, not LVSD, was significantly related to physical function and body 
composition in MHD patients.  
      
  We also found correlations between body composition (LM%) and body size (BMI) and 
cardiac function in MHD patients. Previous studies demonstrated   an unfavorable effect of 
high BMI on mortality when body sizes were assessed separately as LM and fat mass (FM) to 
further stratify wasting symptoms. For example, a high BMI with a low ratio of LM to FM, 
called sarcopenic obesity, was associated with increased systemic inflammation and high 
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mortality rates in MHD patients 211. Apart from mortality data, little is known about the 
contribution of increased body size, and even less with FM or LM, on cardiac function in MHD 
patients. In the present study, patients with LVDD had a higher BMI and lower WBLM% than 
the group without LVDD. Also, decreasing WBLM% was significantly correlated with impaired 
walking capacity (p <0.001, data not shown), but this trend was not significant after controlling 
for body weight in our analysis. Indeed, LM predicts exercise capacity better than total body 
weight in the general population 212. Furthermore, whole body FM was associated with 
unfavorable CV adaptations such as increased blood pressure, impaired LV contractility and 
LVH, whereas increased WBLM was primarily related to preload determinants such as CO and 
SV, perhaps due to the increased metabolic needs of skeletal muscle 213. Taken together, our 
findings suggest body FM and LM should be used to further refine stratification of CV risk in 
relation to cardiac dysfunction in clinical settings in MHD patients. 
 
4-6. Strengths and Limitations 
To our knowledge, this is the first study that assessed the correlation between LV 
diastolic function and functional capacity in MHD patients. This present study excluded patients 
with CV complications that are known to limit physical function. Therefore, the impact of 
LVDD on physical performance was not confounded by other common CV complications in our 
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analysis. However, these exclusions resulted in our study population being younger and fitter 
than the general dialysis population, thus our results may not be valid for older and less fit MHD 
patients. The low prevalence of LVSD may limit the statistical power to detect significant 
difference between groups with and without LVSD. It is possible that use of other criteria to 
identify LVSD such as tissue Doppler S-wave velocity and global strain by speckle tracking 
could have added more precision to our determination of LVSD. However, because there are no 
clinically accepted cut points for defining LVSD using these methodologies, we did not include 
them in this analysis. The most validated technique to estimate LV filling pressures, invasive 
catheters, was not used, and other possible contributors that affect LV diastolic function such as 
left atrial volume and filling profiles and arterial stiffness parameters were not available in this 
study. However, integrated indices using echocardiographic pulsed and tissue Doppler 
assessments that our study used are widely validated to estimate LV filling pressure for LVDD 
classification, and their subclinical prognostic values have been well confirmed in patients with 
ESRD 201. Body composition measures by DXA are fluid dependent, but the measurement 
sessions in our study occurred 24 hours after a dialysis session on a non-dialysis day to minimize 
the effect of fluid overload. Additionally, the design was cross-sectional, making a causal 
relationship impossible.   
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 4-7. Conclusion 
The prevalence of LVDD was higher than LVSD in MHD patients without major CV 
complications such as CHF. The severity of LVDD was related to physical functional capacity 
and body composition in this population. Furthermore, our data suggests that distinguishing 
between body fat and lean mass may improve CV risk stratification in relation to cardiac 
dysfunction. Further investigation is needed to confirm these findings, including in MHD 
patients with diagnosed CV comorbidities.  
 Table 2. Subject Characteristics 
 
 Total (n=82)a 
Patients with 
LVDD (n=40)a 
Patients without  
LVDD (n=42)a  
p-valueb 
Gender (male,%) 48 (58.5%) 17 (42.5%) 31 (73.8%) 0.004 
Age (y) 54.5 ± 12.0 53.7 ± 12.4  55.2 ± 11.8 0.559 
BMI (kg/m2) 31.5 ± 7.2 33.5 ± 7.6 29.5 ± 6.3 0.011 
WBLM (%)  66.2 ± 10.5 62.6 ± 9.0 69.6 ± 10.8 0.002 
BMD (g/cm2) 1.1± 0.2 1.1 ±0.2 1.1 ± 0.2 0.834 
SBP (mmHg) 134.0 ± 28.0  133.2 ± 32.1 134.7 ± 23.9 0.825 
DBP (mmHg) 75.0 ± 16.8 74.4 ± 19 75.8 ± 14.6 0.729  
Smoking status (n, %)  23 (34.2%) 8 (20%) 15 (35.7%) 0.113 
Diabetes (n, %) 40 (48.7%) 21(52.5%) 19 (45.2%) 0.511 
a: Data expressed as mean ± SD for continuous variables and numbers for countable variables  
b: p-value for group difference between patients with and without LVDD  
BMI = body mass index, WBLM = whole body lean mass, LM = lean mass, BMD = whole 
body bone mineral density, SBP = resting brachial systolic blood pressure, DBP= resting 
brachial diastolic blood pressure. 
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Table 3. Cardiac Function Parameters in Patients With and Without LVDD 
 
 Totala 
Patients with 
LVDD (N=40)a  
Patients without  
LVDD (N=42)a 
p-valueb 
  SVI(mL/m2 ) 
   28.3 ± 
14.6 
 25.8 ± 13.2 30.7 ± 15.7 0.144 
  COI (L/m2 )  2.2 ± 21.3 2.1 ± 1.1 2.2 ± 1.5 0.910 
  EF (%) 58.8  ± 18.4 58.4 ± 19.7 59.2 ± 17.3 0.857 
  FS (%) 31.3 ± 14.3 30.5 ± 15.2 32.1 ±13.5 0.648 
  LVMI (g/m2.7) 
   74.9 ± 
40.5 
75.8  ± 40.8 73.9 ± 40.6 0.829 
  LVH (n, %) 62 (87%) 32 (80%) 30 (71.4%) 0.096 
  E/A 1.1 ± 0.4 1.1 ± 0.5 1.0  ± 0.3 0.336 
  E’ (cm/s) 11.0 ± 5.0 8.8  ± 3.9 13.0  ±5.0 < 0.001 
  A’(cm/s)   11.7 ± 4.8   10.5 ± 4 12.7 ± 5.1 0.039 
  E/E’ 7.6 ± 4.3 10.1  ± 4.8 5.5  ± 2.3 < 0.001 
  DT of E (ms) 164.4 ± 75.0 157.1  ± 63.0 171.4  ± 85.1 0.390 
  LVSD (n) 10  5 5 0.868 
a: Data expressed as mean ± SD for continuous values and a number for countable values. 
b: p-value for group differences between patients with and without LV DD, , SVI= stroke 
volume indexed by BSA, COI= cardiac output indexed by BSA , EF= ejection fraction, FS= 
fractional shortening, LVMI: left ventricular mass index; LVM/height2.7, LVH= left ventricular 
hypertrophy, E/A= the ratio of early / late diastolic mitral valve flow velocity, E’= peak early 
diastolic mitral annulus velocity, A’= peak late diastolic mitral annulus velocity, DT of E= 
deceleration time of early diastolic mitral valve flow (E), LVSD: left ventricular systolic 
dysfunction. 
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Table 4. Univariate and Multivariate Predictors of Physical Performance in ISWT and Leg 
Strength   
  ISWT  Univariate model Multivariable model 1 Multivariable model 2 
  Adjusted R2 = 0.203, 
p < 0.001 
Adjusted R2 = 0.338, 
p < 0.001 
 β p β p β P 
LVDD -.303 0.007 -.307 0.004 -.187  0.116  
Age -.359 0.001 -.361 0.001 -.335 0.001 
BMI -.254 0.025 -.226  0.051  .023  0.850  
WBLM% .435 <0.001   .328 0.001 
Diabetes -.369 < 0.001   -.290 0.004 
 
Leg 
Strength 
Univariate model Multivariable model 3 Multivariable model 4 
  Adjusted R2 = 0.044, 
p = 0.039 
Adjusted R2 = 0.098, 
p = 0.004 
 β p β p β P 
LVDD -.238 0.039 -.238 0.039 -.159  0.179  
Age -.180 0.119 -.194 0.087 -.152 0.174 
BMI -.108 0.355 -.047  0.694  .240  0.135  
WBLM% .332 0.004   .332 0.004 
Diabetes -.008 0.944   -.084 0.469 
The relationship between LVDD presence and ISWT and leg strength performance and potential 
confounders (age, BMI, WBLM, diabetes status) of these associations were tested in univariate 
regression analysis. Multivariable Model 1 and 3 tested multivariable prediction of LVDD, age 
and BMI on ISWT and leg strength respectively. Multivariable Model 2 and 4 added WBLM and 
diabetes status into Model 1 and 3.  
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Table 5. Demographic, Physical and Cardiac Function Parameters in Patients With and 
Without LVSD 
 
 
Patients with LVSD 
(N=10)a  
Patients without  
LVSD (N=71)a 
p-valueb 
 Age (y)   54.9 ± 11.3 54.4 ± 12.2 0.905 
 BMI (kg/m2)   32.5 ± 8.0 31.3 ± 7.1 0.631 
 WBLM (%)   64.4 ± 10.3 66.7 ± 10.6 0.520 
Physical Function    
  ISWT (sec) 188.0 ± 102.1 261.4 ± 117.7 0.066 
  Gait speed (m/sec) 0.7 ± 0.2 0.9 ± 0.3 0.125 
Peak torque       
   extension (Nm) 
87.1 ± 34.1 80.3 ± 39.9 0.627 
  Peak torque  
 flexion (Nm) 
41.2 ± 13.8 39.1 ± 21.5 0.780 
Cardiac Function     
  SBP (mmHg) 125.8 ± 26.2 135.6 ± 28.2 0.327 
  DBP (mmHg) 77.3 ± 18.1 74.9 ± 16.9 0.690  
  SVI(mL/m2 )  11.6 ± 5.3 30.8 ± 13.9 < 0.001 
  COI (L/m2 ) 0.9 ± 0.5 2.4 ± 1.3 < 0.001 
  FS (%) 10.5 ± 5.0 34.7 ± 12.2 < 0.001 
  LVMI (g/m2.7)    66.4± 13.5  77.1 ± 42.1 0.111 
  LVH (n, %)   3 (30%)  55 (77.5%) 0.108 
  E/A  1.1 ± 0.5 1.0  ± 0.3 0.336 
  S’ (cm/s)   10.8 ± 4.0 8.9  ±3.7 0.170 
  E’(cm/s)   13.2± 6.0 10.7  ± 4.8 0.160 
  E/E’   5.9 ± 3.3 7.9  ± 4.4 0.225 
  LVDD (n) 5 35 0.615  
a: Data expressed as mean ± SD for continuous values and a number for countable values. 
b: p-value for group differences between patients with and without LVSD,  BMI = body mass 
index, WBLM = whole body lean mass, ISWT = incremental shuttle walk test, SBP = resting 
brachial systolic blood pressure, DBP= resting brachial diastolic blood pressure, SVI= stroke 
volume indexed by BSA, COI= cardiac output indexed by BSA , EF= ejection fraction, FS= 
fractional shortening, LVMI: left ventricular mass index; LVM/height2.7, LVH= left ventricular 
hypertrophy, E/A= the ratio of early / late diastolic mitral valve flow velocity, S’= peak systolic 
mitral annulus velocity, E’= peak early diastolic mitral annulus velocity. 
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Table 6. Abbreviation Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations  Definitions 
BMD Bone mineral density 
BMI Body mass index 
BSA Body Surface Area 
CHF  Congestive Heart Failure 
COI Cardiac output index 
COPD Chronic obstructive pulmonary disease  
CV Cardiovascular 
DBP Diastolic blood pressure 
DT of E Deceleration time of E’ 
DXA Dual emission x-ray absorptiometry  
E/A Diastolic early to late mitral flow velocity ratio 
E’, A’ Peak early / late diastolic mitral annulus velocity 
EF Ejection fraction 
ESRD End-stage renal disease 
FM Fat mass 
FS  Fractional shortening  
ISWT  Incremental shuttle walk test 
LM Lean mass 
LV Left ventricular 
LVDD Left ventricular diastolic dysfunction 
LVH Left ventricular hypertrophy 
LVMI Left ventricular mass index 
LVSD Left ventricular systolic dysfunction 
MHD Maintenance Hemodialysis Patients 
SBP Systolic blood pressure 
SVI Stroke volume index 
WBLM Whole body lean mass 
67 
 
CHAPTER 5 
RESEARCH DESIGN AND METHODS 
5-1. Study Overview 
This study was a cross-over design with 3 randomized conditions. Twenty-eight HD 
patients from local dialysis clinics in Champaign, IL were approached, and 12 agreed to 
participate. Reasons for exclusion were no interest (n=7), not eligible (n=6), transplant (n=1) and 
switching to peritoneal dialysis (n=2). Inclusion/exclusion criteria included the following: 1) 
receive HD treatment at least three days per week;  2) 30-70 years of age; 3) on HD treatment 
for > three months, due to physiological changes that typically occur at the onset of dialysis; 4) 
be physically able to exercise (e.g., no orthopedic problems that would preclude them from 
cycling during dialysis); 5) no chronic obstructive pulmonary disease or decompensated 
congestive heart failure, due to limitations in exercise capacity; 6) receive medical clearance 
from their Nephrologist to participate; 7) have no changes in antihypertensive therapy in the 4 
weeks before enrollment, and unchanged dose and timing of antihypertensive drug intake during 
the trial. All patients provided informed consent and the trial was registered at Clinicaltrials.gov 
NCT02753868. 
 
5-2. Intervention  
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Following the initial screening, patients were assigned to receive each of three treatments in 
a random order during their normally scheduled HD session at the Champaign-Urbana Dialysis 
Clinics. All interventions were administered on the mid-week dialysis session one week apart. 
The interventions included: 1) no intervention control (normal dialysis session), 2) exercise on a 
stationary cycle for 30 minutes starting 30 minutes after the start of ultrafiltration, 3) exercise on 
a stationary cycle for 30 minutes starting 3 hours after the start of ultrafiltration. On days patients 
were asked to exercise, a stationary cycle (Monark Rehab Trainer 881E) was placed in front of 
the dialysis chair and patients were asked to cycle at a self-selected pace and resistance that 
coincides with a subjective exertion between 11 and 13 on the rating of perceived exertion (RPE) 
scale. A series of CV measures were collected before, during, and after each HD session (Figure 
9). 
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5-3. Measurements 
5-3-1. Pre- and Post- HD Testing  
A battery of measurements (described below) were collected on each patient immediately 
prior to, and immediately following their HD sessions on each of the three intervention days.  
For the pre-HD measurements, patients were asked to lay in a supine position for up to 30min 
before the start of HD treatment, during which cardiac and arterial measures and hydration status 
were collected.  The same procedures were conducted immediately after the end of their HD 
treatments.  
Figure 9. Study Overview 
BIS: Bioimpedence Spectroscopy (for hydration status), Cardiac Echo: Cardiac Echocardiography, 
BP: Blood Pressure, CO: Cardiac Output, TPR: Total Peripheral Resistance, ANA: Autonomic 
Nerve System Activity, TFM: Task Force Monitor (thoracic bioimpedance), EX: Exercise, HD: 
Hemodialysis 
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- Cardiac Function: Transthoracic echocardiography was performed (ProSound α-7, Aloka) 
according to the recommendations of the American Society of Echocardiography214. In short, the 
parasternal short-axis view was used to determine left ventricular volumes using the Teichholz 
equation. In the 4-chamber view, early (E) and late (A) flow in to the left ventricle and tissue 
movement (S’, E’ and A’) were measured by Doppler.  
- Arterial Function: Arterial function was measured using an automated BP cuff (Mobil-O-
Graph) that was placed on the non-dialyzing arm of the patient. In addition to standard brachial 
BP measurement, the cuff remained inflated at DBP for 10-15 additional seconds to measure 
pressure wave reflection to calculate augmented pressure (Aix).  This technique also allowed us 
to obtain estimates of central BP at the level of the aorta and arterial stiffness (pulse wave 
velocity). 
- Hydration Status: Whole body hydration status was measured by multi-frequency 
bioimpedence spectroscopy (BIS) (SFB7, Impedimed Inc.,CA,USA). Three measures were 
collected and averaged for analysis. Electrodes and recording pads were placed on the non-
access side of ankle and wrist and connected to the device that utilizes low and high frequency 
currents to estimate extracellular water (ECW), intracellular water (ICW) and total body water 
(TBW). Based on these terms, hydration status, represented as fluid overload (FO) was defined 
using the following variables:  
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Absolute FO: FO (L) = 1.136 * ECW(liter) - 0.430 * ICW (liter) - 0.114 * Body weight(kg)215  
Relative FO: FO% = Absolute FO / ECW) *100 216     
Hyperhydration is defined as: FO% Pre-HD > 15%
216  
Underhydration is defined as: FO% Pre-HD < 6.8%
216  
 
5-3-2. Testing during HD sessions 
The following testing measures were conducted during all three intervention days. 
- Blood Pressure: Brachial BP was measured on the non-dialyzing arm every 15 minutes 
throughout the HD session using an automated BP cuff integrated into the dialysis unit. Aortic 
BP and pulse wave reflection were also obtained every hour using a second automated BP cuff 
(Mobil-O-Graph).  
- Hemodynamics and Autonomic Monitoring: Stroke volume (SV) was continuously 
estimated by transthoracic impedance and used to calculate cardiac output (CO) along with 
ECG-driven heart rate (HR) (Task Force Monitor, CNSystems). Beat-to-beat peripheral BP was 
derived via finger plethysmography and was used to calculate total peripheral resistance (TPR). 
Finger BP measurements were collected for 10 minutes, at 30 minute intervals throughout the 
treatment, using a finger cuff placed on the index and middle fingers of the arm not containing 
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the vascular access.  Intermittent finger cuff measurements (as opposed to continuous) were 
done so as not to interfere with clinic BP measurements and also to minimize patient burden.     
Measures of autonomic function was measured by heart rate variability (HRV) with the 
intervals between successive heart beats and blood pressure variability (BPV) with the beat-to-
beat peripheral BP.  Frequency domain analysis using Fast Fourier transformation generates 
low-frequency (LF, 0.04–0.15 Hz) and high-frequency (HF, 0.15–0.40 Hz) components by an 
autoregressive model, from which the LF/HF ratio is calculated. The LF band of HRV has been 
shown to be associated with baroreceptor-mediated regulation of BP and suggests a mixed 
modulation of sympathetic and parasympathetic activities. The HF component of HRV reflects 
vagal modulation of the sinoatrial node and is thus used a surrogate marker of parasympathetic 
modulation. LF/HF ratio is suggested to be an index of sympathovagal balance, with high values 
suggesting sympathetic predominance. Normalized units of LF and HF to the total power (LFnu 
and HFnu, respectively) were also calculated. BPV analysis provides information related to 
sympathetic modulation through the LF component measures. 
Baroreflex sensitivity (BRS), an index of arterial baroreflex function, was estimated using 
the spontaneous sequence method. Time series of R-R intervals and SBP were analyzed to 
identify sequences in which SBP and R-R interval increased or decreased concurrently over at 
least 3 cardiac cycles. The average value of the individual slopes was taken as the measure of 
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BRS. Data are reported as the average of all beats in each measured time segment to represent 
every 30 minutes throughout an HD treatment. Beats that were greater than 20% different from 
the previous beat were excluded under the assumption that this was an artifact due to patient 
movement.  
- Blood Chemistry: 5mL of blood were drawn from each patient before the start of HD and 30 
seconds after the end of HD session with the help of clinic nursing staff. The blood samples were 
used to measure changes in serum albumin, glucose, calcium and phosphorus using an auto 
analyzer (Piccolo Xpress®, POCT Ltd) and Piccolo® Renal Panels.   
- Intradialytic CV-adverse Events and Symptoms Assessment   
Hypotension-related intradialytic adverse events were defined as one or both of the following 
conditions recorded during a HD session: (i) a fall of SBP to less than 90 mmHg during HD, 
and/or (ii) a fall of SBP of more than 25% from the start of dialysis associated with symptoms 
related to hypotension, including dizziness, vomiting, nausea, and muscle cramps, and may 
require an intervention to be corrected (modifying dialysate temperature, stopping ultrafiltration, 
or saline solution boluses to increase SBP to 100-110 mm Hg)217. Hypertension-related 
intradialytic adverse events were defined as an increase in mean BP over 15mmHg during or 
after a HD session218. 
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Intradialytic symptoms were subjectively assessed by asking patients to complete a 
questionnaire immediately following HD to describe the nature and severity of symptoms 
experienced during the preceding treatment. The questionnaire was created based on the previous 
literature reported detailed methodologies of collection of intradialytic symptoms. The 
questionnaire included symptoms of nausea, dizziness and cramps, stratified severity of none, 
trivial, mild, moderate, and severe and scored 0, 1, 2, 3, or 4, respectively. Post-HD symptoms 
were collected using the same questionnaire and the Fatigue Severity Scale (FSS) questionnaire 
by contacting patients over the phone 5-hours after the preceding HD treatment was ended219. 
FSS questionnaire measures levels of fatigue with stratified scales from 0 being worse to 10 
being normal and includes nine statements designed to evaluate different dimensions of fatigue: 
general fatigue, physical fatigue, motivation, interfering with work, family or social life220.    
 
5-3-3. Clinical factors 
A variety of information from clinic records related to the patient’s treatment were collected. 
This includes intradialytic BP changes for the last two weeks prior to the intervention to monitor 
the typical BP response to HD, the participant’s interdialytic weight gain (IDWG) since the 
previous treatment, the volume of fluid removed during the treatment, the composition of the 
dialysate used during the treatment, and the rate of flow of both the blood and dialysate through 
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the hemodialysis machine during the treatment. Monthly standard blood chemistry values were 
collected from each participant from the month prior to their enrollment. These values included 
serum albumin, phosphorus, and calcium.  
The participants were asked to refrain from using non-steroidal anti-inflammatory (NSAID) 
medications for 7 days prior to the study, as this may affect the results from this study.  
Additionally, on the day of testing the participant were asked to refrain from drinking caffeinated 
beverages.   
 
5-4. Statistical Analysis  
Variables collected at pre- and post-HD were compared by paired t-tests and also tested for 
difference between three intervention days by one-way analysis of variance (ANOVA). As a 
primary analysis, the changes in hemodynamic variables during HD were analyzed by Mixed 
Model Analysis with Repeated Measures with fixed effects of Exercise (CON, 1st-hour EX and 
3rd-hour EX) and Time and a random effect of patients to control for their associated intraclass 
correlation. This analysis was conducted both in the pool of all participating patients (n=12) and 
in the subset of patients who completed all three intervention sessions (n=8). This model also 
tolerates the necessarily unequal number of response variables. To examine the influence of 
hydration status on intradialytic hemodynamic changes, markers of hydration status 
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(ultrafiltration goal volume, IDWG and FO) were additionally entered into the same models. 
Furthermore, between group comparisons were conducted to examine the difference among three 
intervention days at each measured time point (i.e.,15-minute interval for BP and 30-minute 
interval for cardiac and autonomic data) throughout HD. For example for SBP, both the absolute 
(SBPi-min, the level of SBP at i-minutes into HD) and the difference (“delta”) values between the 
beginning and i-minutes of HD (ΔSBPi – 0-min = SBPi-min - SBP0-min) were compared between three 
intervention days by one-way ANOVA. For the cardiac and autonomic data, their time 
annotations in delta values reflect an end time of a 30-minutes interval (i.e., ΔSV60-30min = 
SV30~60min - SV0~30min). When a significance was presented by ANOVA, LSD post-hoc analysis 
was used to further elucidate the difference between two groups. Primary outcomes include 
intradialytic changes in BP, CO and TPR. Secondary outcomes include intradialytic changes in 
markers of arterial stiffness and autonomic activity. LF and HF measures in HRV and BPV data 
were not normally distributed by Shapiro-Wilks tests, and thus the log transformed variables of 
LF and HF were used for analysis. 
Secondary analysis was performed to enhance our understanding of the factors influencing BP 
regulation during HD. Independent determinants of SBP changes during HD were explored by 
entering each target variable (CO, SV, HR, TPR, LFnu and LF/HF) into the Mixed Model with 
Repeated Measures as a covariate. Correlation between the delta values of different 
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hemodynamic variables were also examined by Pearson Correlation tests. Clinical and 
hemodynamic factors were compared between HD sessions with and without IDH or IDHPT. 
SAS version 9.4 (SAS Inc.) and SPSS version 22.0 SPSS Inc.) were utilized for data analysis, 
with P < 0.05 considered statistically significant.  
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CHAPTER 6 
RESULTS 
 
6-1. Patient characteristics  
Descriptive characteristics of study participants are presented in Table 7. Patients were 
predominantly African American and all except one patient had hypertension. Three patients 
completed two intervention days (CON and 1st-hr EX but not 3rd-hr EX) because they no longer 
wanted to participate, and one patient only finished the CON day due to an ankle injury not 
related to the study. Thus, the number of patients completing CON, 1st-hr EX, and 3rd-hr EX was 
12, 11, and 8, respectively.   
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Table 7. Patient Characteristics 
Characteristics (n=12) Mean ± SD 
Age (yr) 55.9 ± 8.6 
Height (cm) 171.5 ± 10.0 
Body Weight at pre-HD (kg) 83.3 ± 20.2 
BMI (kg/m2) 48.5 ± 14.6  
Gender (male/female) 7 / 5 
Race   
   African American (n, %) 10 (83.3%) 
   Caucasian (n, %) 2 (16.7%) 
Diabetes (n, %) 4 (33.3%) 
Hypertension (n, %) 11 (91.7%) 
Smoking (n, %) 8 (66.7%) 
Albumin (g/dL)  3.9 ± 0.3 
Hemoglobin (g/dL) 32.0 ± 7.2 
iPTH (pg/mL) 583.6 ± 394.9 
Calcium (mg/dL)  8.5 ± 0.8 
Phosphorus (g/dL) 5.3 ± 1.7 
Potassium (mEq/L)  4.7 ± 0.5 
Bicarbonate (g/dL) 23.2 ± 2.6  
BUN-to-creatinine  4.9 ± 1.6 
Neutrophil:lymphocyte ratio 2.8 ± 0.9 
 
BMI: body mass index, PTH: parathyroid hormone, BUN: blood urea nitrogen, iPTH: intact 
parathyroid hormone, BUN: blood urea nitrogen  
 
 
6-2. Comparison of treatment-related parameters at Pre- and Post-HD 
A comparison of HD treatment-related parameters across the three treatment days, 
including weights, hydration status, blood chemistries, and intradialytic symptoms are presented 
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in Table 8. While a number of variables related to fluid status and solute concentration changed 
in expected directions between the pre- and post-HD measurements, there were no significant 
differences in these variables across the different treatment days.  
Out of the thirty-one HD sessions, ten and five sessions were identified as HD sessions with 
IDH and IDHTP, respectively. Seven sessions with IDH were symptomatic. In sessions with and 
without IDH, pre-HD and delta values from the beginning to end of HD were compared for 
selected CV characteristics, including SV, CO, TPR, LFnu, and BRS. No difference was found 
between the sessions with and without IDH (data no shown).   
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Table 8. Treatment-related parameters, Hydration Status, and Blood Parameters at Pre- 
and Post-HD  
Variables  Total      CON 1st-hr EX  3rd-hr EX  
IDWG (kg) 2.3 ± 1.1 2.2 ± 1.1 2.4 ± 1.1 2.3 ± 1.1 
Ultrafiltration Goal (L) 2.83 ± 1.09 2.94 ± 0.84 2.74 ± 1.14 2.77 ± 1.44 
Body Weight at pre-HD (kg) 83.3 ± 20.2  84.0 ± 20.8 85.0 ± 22.9 80.0 ± 17.4 
Body Weight at post-HD (kg) 82.1 ± 21.3*  83.1 ± 22.2 84.6 ± 24.1 77.5 ± 18.4 
Hydration Status Parameters     
TBW at pre-HD (L) 49.5 ± 9.4 49.9 ± 9.4 50.6 ± 11.3 47.4 ± 6.8 
TBW at post-HD (L) 46.0 ± 6.9* 45.7 ± 6.9 46.6 ± 7.6 45.6± 6.6 
TBW at pre-HD (%) 61.0 ± 11.5 61.3 ±14.3 60.7 ± 10.1 61.0 ± 10.0 
TBW at post-HD (%) 58.6 ± 11.6* 58.4 ±11.8 57.7 ± 12.9 60.1 ± 11.2 
ECW at pre-HD (L)  21.7 ± 2.8 21.8 ± 2.6 22.1 ± 3.6 21.0 ± 1.9 
ECW at post-HD (L)  19.7 ± 2.2* 19.6 ± 2.3 20.0 ± 2.7 19.4 ± 1.5 
ECW at pre-HD (%)  44.3 ± 3.5 44.3 ± 4.3 44.2 ± 3.4 44.6 ± 2.7 
ECW at post-HD (%)  42.3 ± 4.3* 41.6 ± 5.3 43.4 ± 3.4 43.0 ± 3.9 
ICW at pre-HD (L) 27.8 ± 7.1 28.1 ± 7.6 28.5 ± 8.1 26.4 ± 5.1 
ICW at post-HD (L)  26.5 ± 5.4* 26.7 ± 5.8 26.6 ± 5.5 26.2 ± 5.7 
ICW at pre-HD (%)  55.7 ± 3.5 55.7 ± 4.3 55.8 ± 3.4 55.4 ± 2.7 
ICW at post-HD (%)  56.8 ± 3.5* 57.4 ± 3.3 56.0 ± 3.6 57.0 ± 3.9 
FO at pre-HD (L)  10.7 ± 4.6 10.4 ± 5.4 11.5 ± 3.8 10.0 ± 4.9 
FO at post-HD (L)  8.9 ± 4.4* 8.3 ± 4.6 10.0 ± 4.0 8.3 ± 4.8 
FO at pre-HD (%)  48.9 ± 19.8 47.2 ± 22.7 52.0 ± 15.0 47.1 ± 22.9 
FO at post-HD (%)  44.5 ± 21.0* 42.09 ± 22.9 48.5 ± 17.5 42.8 ± 24.4 
Blood Markers     
Glucose at pre-HD (mg/dL)  99.9 ± 25 104.7 ± 37 99.2 ± 17 92.9 ± 6 
Glucose at post-HD (mg/dL)  108 ± 29* 104 ± 32 114 ± 35 106 ± 15 
BUN at pre-HD (mg/dL)  47.2 ± 11.0 43.2 ± 8.8 47.1 ± 9.7 54.1 ± 14.0 
BUN at post-HD (mg/dL) 11.4 ± 4.0* 10.1 ± 2.8 12.1 ± 4.4 12.6 ± 4.6 
Calcium at pre-HD (mg/dL) 8.6 ± 0.9 8.5 ± 0.9 8.6 ± 0.9 8.7 ± 1.0 
Calcium at post-HD (mg/dL) 8.5 ± 0.4* 8.5 ± 0.4 8.5 ± 0.4 8.6 ± 0.5 
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IDWG: interdialytic weight gain, HD: hemodialysis, TBW: total body water, ECW: 
extracellular water, ICW: intracellular water, FO: fluid overload, BUN: blood urea nitrogen, 
Na: Natrium, K: potassium, IDH: intradialytic hypotension, IDHPT: intradialytic 
hypertension  
    *: indicates a significant difference between pre- and post-HD levels by paired t-test. 
ǂ : Represents an analysis of data from patients who completed all the three interventions (N = 
8). 
  
Table 8 (cont.)     
Variables  Total      CON 1st-hr EX  3rd-hr EX  
Creatinine at pre-HD (mg/dL) 9.9 ± 2.6 9.9 ± 2.3 10.0 ± 2.5 10.0 ± 3.5 
Creatinine at post-HD (mg/dL) 3.0 ± 1.1* 3.0 ± 1.1 3.2 ± 1.0 3.0 ± 1.3 
Albumin at pre-HD (g/dL) 3.2 ± 0.3 3.2 ± 0.3 3.2 ± 0.3 3.1 ± 0.3 
Albumin at post-HD(g/dL)   3.6 ± 0.5* 3.6 ± 0.4 3.5 ± 0.5 3.7 ± 0.7 
Phosphorus at pre-HD (mg/dL) 5.8 ± 1.5 5.6 ± 1.4 6.0 ± 1.6 6.1 ± 1.7 
Phosphorus at post-HD (mg/dL)  2.0 ± 0.5* 2.0 ± 0.5 2.1 ± 0.6 2.0 ± 0.5 
Na at pre-HD (mmol/L)  140.5 ± 4.4 140.8 ± 4.7 139.3 ± 4.4 141.4 ± 4.1 
Na at post-HD (mmol/L)  140.5 ± 4.4 140.8 ± 4.7 139.3 ± 4.4 141.0 ± 1.6 
K at pre-HD (mmol/L)  5.9 ± 0.6 5.9 ± 0.6 6.1 ± 0.6 5.6 ± 0.5 
K at post-HD (mmol/L)  3.6 ± 0.3* 3.6 ± 0.3 3.6 ± 0.3 3.6 ± 0.4 
Physical Symptomsǂ        
Nausea during HD (0~4) 0.5 ± 1.0 0.3 ± 0.7 0.8 ± 1.5 0.4 ± 0.7 
Dizziness during HD (0~4) 0.4 ± 1.0 0.3 ± 0.7 0.6 ± 1.2 0.4 ± 1.1 
Cramping during HD (0~4) 1.0 ± 1.1 0.9 ± 1.0 1.1 ± 1.4 1.0 ± 1.2 
Nausea at 5hr-post-HD (0~4) 0.5 ± 1.3 0.0 ± 0.0 0.6 ± 1.5 0.8 ± 1.6 
Dizziness at 5hr-post-HD (0~4) 0.5 ± 1.3 0.0 ± 0.0 0.4 ± 1.1 1.0 ± 2.0 
Cramping at 5hr-post-HD (0~4) 0.9 ± 1.4 0.8 ± 1.8 0.7 ± 1.3 1.3 ± 1.5 
Fatigue at 5hr-post-HD (0~10) 5.2 ± 2.9 4.8 ± 2.6 5.3 ± 3.4 5.7 ± 3.8 
IDH & IDHPTǂ     
IDH (HD session, n) 8 2 2 4 
IDHPT(HD session, n) 3 1 1 1 
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6-3. Change in brachial hemodynamics during HD (Figure 10 A~G)   
There was no significant Time * Exercise interaction for any of the brachial 
hemodynamic parameters including brachial SBP (F2,28 = 0.9, p = 0.4176), MAP (F2,28 = 0.53, p 
= 0.5942) and PP (F2,28 = 1.16, p = 0.3276). The analysis including only the patients who 
completed all three interventions demonstrated the similar results for brachial SBP (F2,21 = 0.=76, 
p = 0.479), MAP (F2,21 = 0.33, p = 0.720 and PP (F2,21 = 1.63, p = 0.219). This indicates that 
brachial hemodynamic changes during HD were similar between treatment days, regardless of if 
or when the patients exercised. However, there was a significant effect of Time with a decreasing 
trend in the overall population in brachial SBP (F1,28 = 20.06 for all patients and F1,21 = 12.22 for 
patients who completed the three interventions, p < 0.001 for all), MAP (F1,28 = 17.35, F1,21 = 
11.06 for patients who completed the three interventions, p < 0.001 for all) and PP (F1,28 = 16.34, 
F1,21 = 10.79 for patients who completed the three interventions, p < 0.001 for all). Similar trends 
were seen when the influence of fluid status (IDWG, UF goal and FO%) was added as a 
covariate in the model. Between group-comparisons demonstrated no difference in SBP at 0- and 
30-minutes into HD, but a significant difference was found after 60-minutes into HD between 
the three intervention days. Post-hoc analysis showed that the SBP during 3rd-hr EX day were 
lower than CON day at 90, 105, and 135 minutes, and lower than 1st-hr EX day at both 90 and 
165-minutes into HD (p <0.05 for all). Interestingly, SBP on the 1st-hr EX day was significantly 
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higher than the other two days in the later hours of HD (at 210 and 225 minutes), p <0.05 for all). 
No significant difference between intervention days were found for the delta values (ΔSBPi – 0-
min). Despite the numerical increases in ΔSBP60 – 0min and ΔSBP60 – 30min during the 1st-hr EX day 
compared to other intervention days, the difference did not reach the statistical significance, 
partly due to the large variability between patients. The data on MAP showed similar trends to 
the results for SBP.    
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Figure 10-A. Changes in brachial systolic blood pressure during a standard HD treatment with 
and without exercise. 
  
#: indicates a significant effect of Time in the overall group (p<0.05).  
§: indicates a significant difference between 1st-hour IDEX and CON and 3rd-hour IDEX. 
*: indicates a significant difference between 3rd-hour IDEX and CON. 
†: indicates a significant difference between 3rd-hour IDEX and 1st-hour IDEX. 
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Figure 10-B. Changes in brachial diastolic blood pressure during a standard HD treatment with 
and without exercise. 
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Figure 10-C. Changes in mean arterial blood pressure during a standard HD treatment with and 
without exercise.   
 
#: indicates a significant effect of Time in the overall group (p<0.05).  
§: indicates a significant difference between 1st-hour IDEX and CON and 3rd-hour IDEX. 
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Figure 10-D. Changes in brachial pulse pressure during a standard HD treatment with and 
without exercise.  
 
#: indicates a significant effect of Time in the overall group (p<0.05).  
§: indicates a significant difference between 1st-hour IDEX and CON and 3rd-hour IDEX. 
*: indicates a significant difference between 3rd-hour IDEX and CON and 1st-hour IDEX. 
†: indicates a significant difference between 3rd-hour IDEX and 1st-hour IDEX. 
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Figure 10-E. Individual changes in brachial blood pressure during a standard HD treatment 
without IDEX. 
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Figure 10-F. Individual changes in brachial blood pressure during a standard HD treatment with 
exercise during the 1st hour of treatment . 
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Figure 10-G. Individual changes in brachial blood pressure during a standard HD treatment with 
exercise during the 3rd hour of treatment. 
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6-4. Change in aortic hemodynamics during HD (Figure 11 A~E)   
Aortic hemodynamics were measured every hour during HD and the measurement at pre-
HD was included in the Mixed Model with Repeated Measures. There was no significant Time * 
Exercise interaction for any aortic hemodynamic parameter including aortic SBP (F2,22 = 2.44, p 
= 0.110), PP (F2,22 = 1.47, p = 0.252), AugP (F2,22 = 0.27, p = 0.763), Aix75 (F2,22 = 0.92, p = 
0.414) and PWV (F2,22 = 2.65, p = 0.093). This indicates that changes in hemodynamic variables 
across a dialysis session did not differ between treatment days. There was a significant main 
effect of Time, with a decreasing trend in the overall population in aortic SBP (F1,22 = 8.45, p = 
0.0082) and PWV (F1,22 = 5.59, p =0.027) but not in aortic PP (F1,22 = 2.09, p = 0.162), AugP 
(F1,22 = 0.2, p = 0.662) and Aix75 (F1,22 = 0.4, p = 0.533). Similar trends were seen when the 
influence of fluid status (IDWG, UF goal and FO%) were added as a covariate in the model.   
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Figure 11-A. Changes in aortic systolic blood pressure (SBP) during a standard HD treatment 
with and without exercise.  
 
 
#: indicates a significant effect of Time in the overall group (p<0.05).   
*: indicates a significant difference between 3rd-hour IDEX and CON. 
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Figure 11-B. Changes in aortic diastolic blood pressure (DBP) during a standard HD treatment 
with and without exercise.  
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Figure 11-C. Changes in aortic pulse pressure during a standard HD treatment with and without 
exercise.  
 
*: indicates a significant difference between 3rd-hour IDEX and CON. 
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Figure 11-D. Changes in augmentation index at heart rate75 (Aix HR@75) during a standard 
HD treatment with and without exercise.  
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Figure 11-E. Changes in pulse wave velocity during a standard HD treatment with and without 
exercise.  
 
#: indicates a significant effect of Time in the overall group (p<0.05).   
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6-5. Change in cardiac hemodynamics and peripheral vascular resistance during HD 
(Figure 12 A~K)   
SV, HR, CO and TPR were continuously measured during HD, and the beat-to-beat 
values were averaged every 30 minutes for analysis. There was no significant Time * Exercise 
interaction for any cardiac hemodynamic parameter including SV (F2,28 = 1.25, p = 0.303), SI 
(F2,28 = 1.26, p = 0.298), CO (F2,28 = 3, p = 0.066) and CI (F2,28 = 3.01, p =0.065) and TPR (F2,22 
= 2.65, p = 0.093). The analysis including only the patients who completed all three interventions 
demonstrated similar results in brachial SV (F2,21 = 1.09, p = 0.354), CO (F2,21 = 3.22, p = 0.062 
and TPR (F2,21 = 0.93, p = 0.412). This indicates that changes in cardiac hemodynamics and 
vascular resistance during HD were similar across the treatment days. Similar trends were seen 
when the influence of fluid status (IDWG, UF goal and FO%) were added as covariates in the 
model.  
Between-group comparisons at each measured time point demonstrated a significant 
difference in CO, CI and left ventricular ejection time between the intervention days 30 to 60 
minutes into HD during which the 1st-hour IDEX was performed. Post-hoc analysis showed that 
1st-hr EX day had higher CO, CI and HR, and shorter left ventricular ejection time compared to 
the other two treatment days at these time points. (p <0.05 for all). On the 3rd-hr EX day, there 
was a higher SV, CO and CI at 150- and 180-minutes into HD during which the 3rd-hour IDEX 
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was performed, compared to the other intervention days (p <0.05 for all). Using the cardiac delta 
values, similar trends for exercise-induced increases in SV and CO were seen during the time 
intervals when IDEX was performed: increased ΔSV60-30 and ΔCO60-30 in 1st-hr EX day; and 
increased ΔSV120-30 and ΔCO120-30 in 3rd-hr EX day (p < 0.05 for all). There was a numerical 
decrease in TPR before and after the 3rd-hour IDEX (mean ΔTPR240-180 = -222.87, CI: (-627.79, 
178.03), p = 0.174). When compared to 1st-hour IDEX, there was a trend for a difference in 
ΔTPR240-180 in 3rd-hour IDEX (mean difference= -386.48, CI= (-804.97, 31.99) and p=0.068). 
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Figure 12-A. Changes in stroke volume during a standard HD treatment with and without 
exercise.  
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Figure 12-B. Changes in cardiac output during a standard HD treatment with and without 
exercise.  
 
 
§: indicates a significant difference between 1st-hour IDEX and CON and 3rd-hour IDEX. 
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Figure 12-C. Changes in cardiac output index during a standard HD treatment with and without 
exercise.  
 
 
§: indicates a significant difference between 1st-hour IDEX and CON and 3rd-hour IDEX. 
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Figure 12-D. Changes in total peripheral resistance during a standard HD treatment with and 
without exercise.  
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Figure 12-E. Changes in heart rate during a standard HD treatment with and without exercise.  
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Figure 12-F. Individual changes in stroke volume during a standard HD treatment without 
exercise.  
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Figure 12-G. Individual changes in stroke volume during a standard HD treatment with exercise 
during the 1st hour of treatment.  
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Figure 12-H. Individual changes in stroke volume during a standard HD treatment with exercise 
during the 3rd hour of treatment.  
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Figure 12-I. Individual changes in cardiac output during a standard HD treatment without 
exercise.  
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Figure 12-J. Individual changes in stroke volume during a standard HD treatment with exercise 
during the 1st hour of treatment. 
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Figure 12-K. Individual changes in stroke volume during a standard HD treatment with exercise 
during the 3rd hour of treatment.  
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6-6. Change in autonomic function by heart rate variability and blood pressure variability 
during HD (Figure 13 A~D)  
LF, HF, LFnu, HFnu and LF/HF by HRV and BPV were continuously measured and 
averaged every 30 minutes throughout HD for analysis. There was no significant interaction 
effect of Time * Exercise for any autonomic function parameters including LF by HRV (F2,28 = 
0.36, p = 0.701), HF by HRV (F2,28 = 0.08, p = 0.946), LFnu by HRV (F2,28 = 0.54, p = 0.587), 
HFnu by HRV (F2,28 = 0.43, p = 0.653), LF/HF by HRV (F2,28 = 1.32, p = 0.282), PSD (F2,25 = 
0.07, p =0.930), LF by BPV (F2,27 = 0.65, p = 0.531), HF by BPV (F2,27 = 0.08, p = 0.925), LFnu 
by BPV (F2,27 = 0.2, p = 0.823), HFnu by BPV (F2,27 = 0.95, p = 0.399), LF/HF by BPV (F2,27 = 
0.54, p = 0.588), BRS (F2,24 = 0.76, p =0.477) and BEI (F2,24 = 0.12, p =0.884). This indicates 
that autonomic function changes during HD did not behave differently between intervention 
days. However, there was a significant effect of Time with an increasing trend in LFnu by HRV 
(F1,28 = 6.85, p = 0.014) and a decreasing trend in HF by HRV (F1,28 = 4.58, p = 0.041) and HFnu 
by HRV (F1,28 = 6.88, p = 0.013) in the overall population. The ratio of LF/HF by HRV ratio 
showed a borderline significant increasing trend (F1,28 = 3.92, p = 0.057). Similar trends for 
changes in autonomic variables were seen in the analysis including only the subset of patients 
who completed all three interventions, or when the influence of fluid status (IDWG, UF goal and 
FO%) was added as a covariate in the model. Between-group comparisons by ANOVA showed 
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no difference at each measured time point in the absolute and the delta values of autonomic 
parameters.  
 
Figure 13-A. Changes in normalized low frequency component of heart rate variability (HRV) 
during a standard HD treatment with and without exercise.  
 
 
#: indicates a significant effect of Time in the overall group (p<0.05).   
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Figure 13-B. Changes in normalized high frequency component of heart rate variability (HRV) 
during a standard HD treatment with and without exercise.  
 
 
 
#: indicates a significant effect of Time in the overall group (p<0.05).   
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Figure 13-C. Changes in low to high frequency ratio of heart rate variability (HRV) during a 
standard HD treatment with and without exercise.  
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Figure 13-D. Changes in baroreflex sensitivity during a standard HD treatment with and without 
exercise.  
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6-7. Comparison of cardiac and arterial parameters at Pre- and Post-HD 
Cardiac and arterial parameters before and after HD on the three treatment days were 
obtained in a subset of participants and are summarized in Table 9. Due to patient’s time 
constraints before or after treatment, this data was only collected on 8, 6, and 3 patients on the 
CON, 1st-hour IDEX, and 3rd-hou IDEX days, respectively. There was no difference between 
three intervention days in all parameters measured at pre- and post-HD with the exception of 
AugP and Aix75. Post-hoc analysis indicated that AugP and Aix75 at post-HD in the 3rd-hr EX 
was significantly lower than those in 1st-hr IDEX (p<0.05 for both). Body weight and all 
hydration related variables at post-HD were significantly lower than pre-HD values. Among 
cardiac and arterial variables, only E/E’ at post-HD was significantly different from the pre-HD 
value when all data was combined.       
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Table 9. Cardiac and Arterial Parameters at Pre- and Post-HD 
 
Variables Total CON  1st-hr EX 3rd-hr EX 
Cardiac Parameters    (n=8) (n=6)  (n=3)  
SV at pre-HD (mL) 73.2 ± 23.4  74.5 ± 24.9 74.2 ± 24.5 67.7 ± 25.7 
SV at pre-HD (mL) 67.5 ± 30.3  81.2 ± 41.6 58.7 ± 15.8 53.0 ± 2.8 
CO at pre-HD (L) 5.4 ± 1.7 5.7 ± 1.6 5.5 ± 1.9 4.4 ± 1.6 
CO at post-HD (L) 5.1 ± 2.7 6.4 ±3.5 4.5 ± 1.8 3.4 ± 0.6 
EF at pre-HD (%)  57.8 ± 18.7 63.0 ± 18.5 55.2 ± 20.0 49.2 ± 19.0 
EF at post-HD (%)  59.7 ± 17.6 64.2 ± 8.2 57.1 ± 22.4 54.1 ± 30.8 
E/A at pre-HD   1.1 ± 0.2 1.1 ± 0.2 1.2 ± 0.2 1.0 ± 0.0 
E/A at post-HD   0.9 ± 0.2 0.9 ± 0.3 0.9 ± 0.1 1.0 ± 0.2 
S’ at pre-HD  8.7 ± 1.9 8.9 ± 2.6 8.9 ± 1.6 8.1 ± 1.2 
S’ at post-HD  8.8 ± 2.1 9.6 ± 1.9 8.5 ± 2.5 7.6 ± 1.1 
E’ at pre-HD  10.5 ± 3.4 9.8 ± 3.0 11.4 ± 4.8 10.4 ± 1.6 
E’ at post-HD 9.2 ± 2.3 9.1 ± 1.7 9.8 ± 2.8 8.3 ± 2.9 
A’ at pre-HD  9.6 ± 3.2 10.0 ± 4.4 9.5 ± 2.6 8.9 ± 1.6 
A’ at post-HD  8.9 ± 2.0 8.6 ± 1.1 9.7 ± 2.9 8.0 ± 1.9 
DecT at pre-HD 168 ± 111 175 ± 126 173 ± 103 144 ± 128 
DecT at post-HD 180 ± 110 196 ± 103 152 ± 91 188 ± 180 
E/E’ at pre-HD  9.6 ± 5.9 10.8 ± 6.4 9.4 ± 7.6 7.5 ± 0.6 
E/E’ at post-HD 7.5 ± 3.8* 7.5 ± 4.1 7.7 ± 4.7 7.2 ± 2.8 
LVM at post-HD (g) 327.8 ± 96.4    
Arterial Parameters  (n=7) (n=6) (n=4) 
bSBP at pre-HD (mmHg) 126.2 ± 19.3 127.6 ± 20.7 130.7 ± 23.8 117.2 ± 6.1 
bSBP at post-HD (mmHg) 132.1 ± 20.6  130.0 ± 17.7 142.7 ± 23.9 116.0 ± 5.0 
bDBP at pre-HD (mmHg) 76.5 ± 17.1 78.4 ± 17.0 79.0 ± 21.5 69.2 ± 11.2 
bDBP at post-HD (mmHg) 77.5 ± 13.5  75.0 ± 9.8 82.8 ± 17.5 71.7 ± 10.7 
aSBP at pre-HD (mmHg) 117.3 ± 19.0  117.3 ± 20.8 122.2 ± 23.0 110.0 ± 7.7 
aSBP at post-HD (mmHg) 120.6 ± 19.6 118.8 ± 17.4 129.5 ± 22.4 106.3 ± 11.2 
aDBP at pre-HD (mmHg) 77.5 ± 17.0  79.7 ± 17.2 80.2 ± 20.9 69.8 ± 11.0 
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SV: stroke volume, CO: cardiac output, EF: ejection fraction, E/A: the ratio of early to late 
diastolic filling pressures, S’: peak systolic annular velocity, E’: peak early diastolic annular 
velocity, A’: peak late diastolic annular velocity, DecT: deceleration time of E’, E/E’: the 
ratio of early diastolic filling  pressure to tissue velocity, LVM: left ventricular mass, bSBP: 
brachial systolic blood pressure, bDBP: brachial diastolic blood pressure, aSBP: aortic 
systolic blood pressure, aDBP: aortic diastolic blood pressure , AugP: augmentation 
pressure, Aix75: Augmentation pressure at heart rate 75, PWV: pulse wave velocity 
   *: indicates a significant difference between pre- and post-HD levels by paired t-test. 
  #: indicates a significant difference between three intervention days by ANOVA and a 
significant difference from 1st-hr EX by LSD-post-hoc analysis. 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9 (cont.)     
Variables Total CON  1st-hr EX 3rd-hr EX 
aDBP at post-HD (mmHg) 78.9 ± 13.5 76.2 ± 10.1 84.7 ± 17.0 72.7 ± 10.7 
AugP at post-HD (mmHg) 8.5 ± 6.0  6.7 ± 4.2 12.8 ± 6.2 3.3 ± 1.5# 
Aix75 at pre-HD (mmHg) 18.3 ± 13.6 17.6 ±13.1 21.7 ± 17.7 14.5 ± 8.7 
Aix75 at post-HD (mmHg) 16.1 ± 12.5 13.5 ± 9.7 24.8 ± 12.4 4.0 ± 3.5# 
PWV at pre-HD (m/s)  8.2 ± 0.7 8.2 ± 0.8 8.1 ± 0.6 8.2 ± 0.6 
PWV at post-HD (m/s)  8.3 ± 0.9 8.3 ± 1.0 8.7 ± 0.5 7.8 ± 0.9 
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6-8. Relationship between hemodynamic changes during HD: Potential determinants of BP 
changes during HD  
The relationship between changes in brachial BP and other hemodynamic variables that 
potentially influence BP levels, including SV, HR, CO, TPR and LFnu were examined by two 
different methods; 1) covariance slope comparison in a Mixed Model with Repeated Measures to 
examine the overall contribution of the potential candidates to BP fluctuation; and 2) correlation 
between delta values to examine the short-term fluctuation.  
 Mixed repeated models with covariance slopes 
In this analysis, SBP was used as a dependent variable with potential hemodynamic 
determinants of SBP fluctuation (SV, HR, CO, TPR and LFnu) added as covariates. When the 
slope of the covariate * Time is not significantly different from the slope of SBP * Time, it can 
be interpreted that the intradialytic change of the covariate is similar to the intradialytic change 
of SBP and thus, potentially has influenced the SBP changes during HD. The results from this 
analysis showed that the slopes of each of hemodynamic parameters except TPR were 
significantly different from the slope of SBP fluctuation during HD; CO (F1,404= 11.99, β-
difference: 1.23, SE: 0.35, p = <0.001), SV (F1,404= 11.99, β-difference: 1.23, SE: 0.35, p = 
<0.001), HR (F1,442= 5.65, β-difference: 1.96, SE: 0.83, p = 0.018) and LFnu (F1,404= 11.99, β-
difference: 1.23, SE: 0.35, p < 0.001). This indicates that intradialytic fluctuations in CO, SV, 
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HR and LFnu were not similar to the change in SBP over the course of a HD treatment. On 
the other hand, the slope of TPR * Time was not significantly different than the slope of SBP 
* Time during HD (F1,414= 0.01, β-difference: -0.675, SE:5.6, p = 0.90), indicating a potential 
relationship between intradialytic changes in TPR and SBP.  
A similar analysis was done to assess factor associated with the change in MAP during HD. 
The slope of MAP * Time was not significantly different from either SV * Time (F1,422= 0.91, β-
difference: 0.30, SE: 0.32, p = 0.342) or TPR *Time (F1,399 = 0.02, β-difference: -0.938, SE: 6.02, 
p < 0.8764).  However, there was a significant slope difference between MAP*Time and CO * 
Time (F1,421 = 8.31, β-difference: 0.63, SE: 0.22, p = <0.004), HR*Time (F1,426 = 3.21, β-
difference: 1.55, SE: 0.87, p = 0.074) and LFnu *Time (F1,390= 8.68, β-difference: 0.862, SE: 0.3, 
p < 0.003). These results indicate that intradialytic changes in MAP were similar to intradialytic 
changes in SV and TPR, but not with CO, HR and LFnu.  
 Correlation analysis between intradialytic change values   
Correlation analysis was performed to assess the relationship between intradialytic changes 
in BP and other hemodynamic variables. There were positive associations between ΔSBP210-0 and 
ΔLFnu210 – 30 (r = 0.624, p = 0.002) and ΔSBP240-30 and ΔLFnu240 –30 (r = 0.928, p = 0.008), 
indicating the magnitude of attenuation in sympathetic activity was related with the magnitude of 
drop in SBP at 210 and 240 minutes from the beginning of HD. Similarly, a significant 
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association between ΔMAP210-0 and ΔLFnu210 – 30 (r = 0.570, p = 0.0007) was noted. ΔSV60 -30 
was negatively associated with ΔTPR60 –30 (r = 0.672, p = 0.001) and ΔSV120-30 was positively 
associated with ΔLFnu120 – 30 (r = 0.400, p = 0.026). This may indicate a coordinated regulation 
of SV and TPR in the early phase of HD, and SV and autonomic function in the later phase of 
HD. Furthermore, the bigger drop in LFnu from the beginning to the end of HD (ΔLFnu240 – 30) 
was associated with higher scales of nausea, dizziness and cramping during HD. Lower aortic 
SBP (r = -0.585, p = 0.022), DBP (r = -0.555, p = 0.012) and PP (r = -0.685, p = 0.0021) at post-
HD were associated with higher cramping during HD.   
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Figure 14-A and B. Association between the changes in systolic blood pressure (A) and mean 
arterial blood pressure (B) and the corresponding changes in normalized unit of low frequency 
from the beginning to 210-minutes into HD.  
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6-9. Association between hydration status and CV characteristics 
Higher UF levels were associated with greater drops in SBP, CO and SV in the later 
hours during HD (ΔSBP 180-0 : r = -0.428, p = 0.046, ΔSBP 210-0 : r = -0.440, p = 0.046, ΔSBP 240-
0 : r = -0.846, p = 0.034, ΔCO210 –30 : r = -0.454, p = 0.013, ΔSV210 –30 : r = -0.436, p = 0.018). 
Furthermore, higher UF goal was linked to lower BRS levels throughout HD (Figure 15 A~E). 
Increased TBW%, ECW (L) and FO (L) at post-HD were associated with higher magnitude of 
EEm, an indicator of diastolic dysfunction. Increased TBW (L), ECW(L) and FO (%) were 
associated with increased aortic SBP levels at post-HD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
 
Figure 15-A~E. Association between ultrafiltration goal and baroreflex sensitivity throughout 
HD.  
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Figure 15 A~E (cont.) 
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CHAPTER 7 
DISCUSSION 
The primary purpose of this study was to evaluate the safety of IDEX by examining its effect 
on intradialytic CV hemodynamics. Specifically, intradialytic changes in brachial, aortic and 
cardiac hemodynamics and autonomic function were examined during a normal HD session 
without exercise, or when 30-minutes of cycling exercise was performed during the 1st- or 3rd-
hour into HD. The primary finding from this study was that IDEX performed during either the 
1st- or 3rd- hour does not appear to exacerbate hemodynamic instability during HD. While there 
were transient increases in SV, CO and HR during IDEX, the intradialytic changes in brachial 
and aortic BP parameters, cardiac hemodynamics and autonomic function were similar on days 
with and without IDEX. This null effect of IDEX on hemodynamic parameters during HD was 
demonstrated regardless of the timing of exercise and patients’ underlying CV characteristics. 
Patient hydration status was correlated with the magnitude of BP drop and autonomic 
dysfunction, and increasing sympathetic activity was also correlated with drops in BP during 
HD. This data suggests potential mechanisms that may contribute to intradialytic hypotension.  
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7-1. Brachial Hemodynamic Response during HD with and without IDEX  
Previous studies have demonstrated that IDEX can improve important health-related outcomes 
including CV function, physical function, and quality of life1-3. Exercise during HD has been 
advocated for its convenience as a time-efficient strategy to increase physical activity during a 
forced sedentary period. However, concerns regarding its potential impact on hemodynamic 
instability has been a cause for concern for clinicians, despite a lack of evidence for these effects. 
HD imparts a significant CV stress mainly due to the progressive loss of blood volume during 
treatment, and exercise may in theory exacerbate these effects. In particular, post exercise 
hypotension (PEH) may increase the risk of ischemic adverse events, particularly during the 
latter phase of HD when the total blood volume is already low. Despite this theoretical concern, 
the present study demonstrated that intradialytic changes in brachial BP parameters were not 
different between HD sessions with and without IDEX performed during either the 1st-hour or 
the 3rd-hour of treatment. This finding is consistent with previous studies in which IDEX was 
well tolerated and did not elicit abnormal hemodynamic responses21, 113, 183, 184, though much of 
the previous data examining the impact of IDEX on hemodynamic variables came from small 
pilot studies lacking a control group. The only previous study that systematically investigated the 
CV safety of IDEX used a short submaximal exercise bout (5-minutes of cycling at 60% of 
VO2peak) that was repeated every hour during an HD treatment. Stable hemodynamic responses 
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to IDEX were demonstrated through the 2nd-hour of HD, but 5 out of 8 patients were unable to 
perform cycling during the 3rd-hour due to hypotension that was accompanied by reductions in 
HR and CO. One potential explanation for this is that the patients that were unable to exercise in 
the 3rd hour due to hypotensive symptoms had a higher ultrafiltration volume compared to the 
patients who were able to exercise in the 3rd-hour (4596±1339 ml vs 3170±1092 ml 
respectively)21. This suggests that exercise may indeed be well tolerated in the 3rd hour of 
treatment in the absence of excessive ultrafiltration requirements, thus does not need to be 
contraindicated in all patients.   
There was a trend for a reduction in both brachial and aortic BP throughout HD across all 
groups. This is a well-known phenomenon likely resulting from the loss of plasma volume 
during HD. The reduction in plasma volume reduces venous return, and if this is not 
compensated by an increase in HR or TPR, there will be a gradual decrease in BP during HD. 
The typical reduction in SBP during HD is around 10~15mmHg, though the reduction is often 
more rapid in the first hour compared to the later hours of treatment221. The average intradialytic 
SBP drop in this study was 18 mmHg, which is comparable to other data in the literature. CO 
and TPR are mutual determinants of mean arterial BP and are expected to behave reciprocally to 
maintain mean arterial BP. In the present study, both CO and TPR were numerically reduced 
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over the course of HD, but these changes were not statistically significant.  This may indicate 
suboptimal compensatory CV responses that are insufficient to maintain BP during HD.  
 
7-2. Cardiac Hemodynamic Response during HD with and without IDEX  
During exercise, peripheral vasodilation occurs to meet the increased metabolic demands in 
exercising muscles. At the same time, local signals integrated from baroreflex, chemoreflex and 
skeletal muscle receptors help to augment sympathetic outflow in the heart, the adrenal gland 
and the splanchnic vasculatures, with the final result of maintained or increased systemic BP 
levels during exercise. In the present study, increases in SV, CO and HR observed during the 
IDEX period indicate that most patients appeared to have a normal CV response to the moderate 
intensity exercise bout. However, we did not observe a reduction in BP following the cessation 
of exercise, a phenomenon known as post-exercise hypotension (PEH).  This is normally 
caused by a post-exercise reduction in TPR. This lack of an effect may have been due to 
autonomic dysfunction, though it could also have been due to the relatively modest intensity of 
the exercise bouts that were conducted. It is also possible that the removal of fluid by 
ultrafiltration prevents the signals that are normally responsible for PEH. The magnitude of local 
vasodilation in active tissues, despite an increased systemic sympathetic outflow, is termed 
“functional sympatholosis”, and normally becomes greater as exercise intensity increases168, 169. 
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Vasoconstriction is one of the important compensatory responses to the progressive hypovolemia 
and thus presumably occurred to some extent in our patients. Furthermore, decreased levels of 
systemic nitric oxide concentration have been reported after HD treatment, suggesting a partial 
reduction in vasodilatory capacity222. Thus, it can be speculated that the effect of mild to 
moderate intensity IDEX on the CV system might be offset by the profound impact of HD, 
resulting in the absence of PEH. Although beyond the scope of the present study, pre-existing 
ESRD-comorbidities, such as autonomic dysfunction, impaired vasoreactive capacity, and HD-
driven increases in systemic inflammation cannot be ruled out as factors responsible for the 
blunted post-exercise responses in HD patients. 
 
7-3. Autonomic Response during HD with and without IDEX 
HRV is a measure of autonomic regulation of heart rate, reflecting the ability of the sinoatrial 
node to modify HR in response to sympathetic and parasympathetic signals. The beat-to-beat 
BPV provides information regarding the relative contribution of neuro-humoral systems in BP 
regulation, including baroreceptor reflex, the renin-angiotensin system, the vascular myogenic 
response, and the endothelial response to nitric oxide223. Spectral analysis provides an analysis of 
HR and BP oscillations at different frequencies. In HRV analysis, oscillations within HF ranges 
and HFnu (normalized HF component over total power) are considered to be a marker of 
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parasympathetic and respiratory modulations. LF oscillations are attributed to the interaction of 
slow sympathetic and fast vagal actions, and LFnu is often accepted as a measure of sympathetic 
nerve activity. BPV at LF domain is modulated by sympathetic vascular activity while BPV at 
HF has shown to be largely influenced by CO224. HD patients are characterized by suppressed 
HRV and BPV and enhanced sympatho-excitation38, 142 and decreased baroreflex sensitivity, a 
measure of HR response to BP fluctuations225.  
In the present study, there was a significant increasing trend in LFnu and decreasing trends in 
HF and HFnu by HRV throughout HD sessions in the overall population, indicating a shift of 
sympathovagal balance toward a sympathetic predominance during HD. While BPV was not 
altered, the HRV data are consistent with previous findings demonstrating increased sympathetic 
activity during a HD treatment41, 130. This trend toward sympathetic activation was inversely 
associated with intradialytic BP in the present study, and helps describe the integrative CV 
regulation in response to HD. HD-driven blood volume depletion causes drops in systemic BP 
and systemic vascular resistance, signaling arterial baroreceptors to augment sympathetic 
activity. Sympathetic outflow is likely to be discharged continuously or at increasing manner 
when the subsequent arterial BP levels do not recover to normal levels. Despite the increasing 
sympathetic and decreasing parasympathetic stimulation, there was no corresponding change in 
HR and TPR throughout HD in the present study. These blunted responses in the heart and the 
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vasculature to the autonomic modulation reflect an impaired CV regulatory capacity and are 
likely to be partly responsible for the failure to maintain BP during HD. In support of this, 
previous studies have demonstrated a high prevalence of autonomic neuropathy226, an impaired 
vascular adrenoceptor number and function227, and decreased vascular response to Ang II228 in 
patients with intradialytic hypotension. 
There is no previous study investigating the acute effect of IDEX on autonomic function, 
though several studies examined the autonomic control during dynamic exercise in HD patients 
on non-HD days. Compromised autonomic regulation in response to exercise has been 
consistently shown, particularly in related to abnormal BP responses142 157 39. In the present 
study, there was no significant effect of IDEX on intradialytic change in autonomic activity, 
including LFnu, HFnu, LF/HF and BRS. The explanation for this is likely to be multifactorial 
and the influence of HD is likely to create disturbances in autonomic modulation. A patient’s 
hydration status229, 230, the composition231 and temperature of the dialysate232, and PTH levels233 
can also influence HRV. Despite the methodological challenges, further investigation of 
autonomic regulation during IDEX is warranted.  
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7-4. Change in Arterial Compliance during HD with and without IDEX  
Given the high CV disease burden in HD patients, measurements of aortic hemodynamics 
provide pathophysiologically important information because central BP reflects the volume and 
pressure load imposed on the left ventricle more accurately than peripheral BP. Apart from 
volume change, arterial stiffness and the magnitude of arterial wave reflection significantly 
influences aortic BP and PP. Accordingly, PWV and Aix have been consistently related to CV 
morbidity and mortality in HD patients88, 234. However, there are conflicting data regarding the 
acute effect of HD treatment on arterial compliance. Decreased Aix235, 236 and aortic PWV237 and 
increased aortic and brachial PWV236, 238 have been shown after HD, though other studies 
indicate no effect of HD on aortic PWV239, 240 and markers of large artery compliance241, 242. 
These inconsistent results might be attributed to methodological and population discrepancies 
between studies, as well as the acute effects of HD on the CV system. In theory, volume 
overload increases arterial distension and consequently augments arterial stiffness according to 
Laplace’s law (T = P · D/2, T: circumferential wall tension, P: internal pressure, D: internal 
diameter). However, with decreasing blood volume as a result of ultrafiltration, the renin 
angiotensin aldosterone (RAA) system is activated and Ang II levels are increased. This results 
in vasoconstriction and arterial stiffness. Furthermore, HD not only creates a huge volume 
fluctuation but also changes levels of some vasoactive molecules that may affect the arterial 
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properties such as endothelin NO and Ang II222.  The timing and amplitude of the reflected 
waves from the peripheral vasculatures to the aorta have been shown to be attenuated following a 
submaximal exercise, which in turn decreases aortic pulse amplification, aortic PP and PWV243. 
While the present study showed no significant effect of IDEX on any aortic hemodynamics, 
there was a significant effect of HD, with decreasing trends in aortic BP and PWV over the 
course of a treatment. However, it should be noted that only a limited number of aortic 
measurements were available from a subgroup of participants in this study, thus limiting the 
validity of the results.    
  
7-5. The Potential Protective Effect of IDEX for IDH 
In the present study, brachial BP levels were elevated in the last hour of HD after performing 
the 1st-hour IDEX. This was in contrast to the progressive decreasing trend in the HD sessions 
either without IDEX or with 3rd-hour IDEX. The challenge of maintaining hemodynamic 
stability during HD, particularly in the later hours, arises mainly from inadequate CV 
compensatory responses to hypovolemia. Although speculative, when total blood volume is 
critically low and the expected compensatory responses are suboptimal, the acute stimulation of 
the CV system by exercise may help maintain CV homeostasis. Exercise engages a wide range of 
mechanisms to increase central blood volume. During exercise, plasma volume diffuses from the 
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intravascular compartment to interstitial space around skeletal muscles. This reduction in plasma 
volume activates autonomic peripheral afferent receptors such as baroreflex, chemoreflex and 
skeletal muscle receptors to increase sympathetic outflow. The efferent responses to the 
sympathetic activation include increased HR and myocardial contractility in the heart, and 
vasoconstriction in non-active organ vasculatures. This sympathetic modulation in the CV 
system as a whole helps increase central blood circulation.  Previous studies demonstrate that 
IDEX indeed produces a transient reduction in plasma volume at the onset of exercise184, 244. 
However, when monitored until the end of HD, the change in relative blood volume was 
gradually increased, compared to during HD without IDEX where there was a gradual decreasing 
trend244. The authors speculated that IDEX has the potential to promote plasma refilling during 
the post-exercise period. Exercise-induced fluid shifts from the intravascular space to the active 
tissues can lead to an increased plasma hematocrit concentration during exercise. This facilitates 
plasma refilling from the extravascular to intravascular compartment due to an increased 
intravascular colloid osmotic pressure after exercise. Furthermore, exercise is proposed to induce 
increased capillary membrane pore sizes to allow efficient nutrient delivery for exercising tissues 
in HD patents109, 245. This decreased inter-compartment resistance may boost the influx of 
interstitial fluid to the intravascular space, at least shortly after exercise is ended, although it is 
unclear how long this effect may last in HD patients. In addition, the local contribution from the 
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muscle pump can accelerate CV refilling via increased venous return and mobilization of 
interstitial fluid. Micromechanical stimulation of calf muscle pump increased CV refilling, as 
evidenced by an initial rapid rise and a longer slow rise in BP, via improved interstitial fluid 
recovery from low extremities in HD patients246. Further studies are needed to examine the 
protective effect of IDEX from the standpoint of development and understanding of non-
pharmacological treatment modalities for HD patients prone to hypotensive events.  
 
7.6 Interplay between Intradialytic Hemodynamic Parameters; Determinants of BP 
changes during HD 
Hemodynamic instability is one of the biggest clinical challenges in HD patients. Thus, 
determining what CV factors influence BP regulation during HD are clinically important. The 
present study examined the relationship between BP and other hemodynamic indices by two 
methods in regard to different time frames: 1) comparison of the slopes of CV indices throughout 
HD and 2) correlation between intradialytic changes between different CV variables during 
specific time frames. The slope-based analysis suggested a contribution of SV to MAP 
intradialytic changes. This supports a dominant role for blood volume changes in determining 
systemic BP levels during HD. The correlation analysis showed that a significant relation 
between the changes in SBP and LFnu from the beginning to the end of HD. This indicates that 
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the degree of attenuation in sympathetic activity was related to the magnitude of drop in SBP in 
the last hour of HD. Likewise, a larger drop in LFnu from the beginning to the end of HD was 
associated with increased incidence of intradialytic symptoms including nausea, dizziness and 
cramping. Lower aortic BP at post-HD was also associated with higher cramping during HD. 
Additionally, a negative correlation between SV and TPR changes during the first-hour and a 
positive association between SV and LFnu changes in the third hour of HD were found. These 
results indicate reduced venous return, as indicated by decreased SV, is compensated by 
increased vascular constriction during the early hour, whereas autonomic regulation plays an 
increasing role to maintain arterial BP in the later hours of HD when circulating blood volume is 
low. However, it should be noted that this analysis included all available HD sessions, 
irrespective of whether or when exercise was conducted. This was done to increase the power of 
the analysis, though may complicate the interpretation of the results. Nevertheless, exercise-
induced hemodynamic fluctuation was only observed during the period of exercise, and all 
primary analysis indicate that the exercise had little impact on most hemodynamic variables.    
  
7.7 Influence of Hydration Status on Intradialytic Hemodynamic Changes  
The magnitude of hydration status, as measured by IDWG, ultrafiltration volume, and FO% at 
pre-HD, did not significantly influence the intradialytic changes of hemodynamic parameters 
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between HD sessions with and without IDEX. The high variability in hydration state within and 
between patients and the heterogeneous intradialytic hemodynamic responses may have limited 
the power to detect an influence of hydration status on intradialytic hemodynamic changes with 
and without IDEX. However, the correlation between hydration status and hemodynamic indices 
revealed that higher ultrafiltration volume was associated with larger drops in SBP, CO and SV 
in the later hours during HD, and lower BRS throughout HD sessions. These results may confirm 
the notion that high IDWG and the consequent high target volume removal during HD is likely 
to increase the risk of HD-intolerance in the later hours of HD. The finding of the dampened 
BRS levels with increased ultrafiltration volume is in line with other data showing a correlation 
between FO and HRV247. As incomplete volume correction during HD contributes to the 
development of chronic FO, our results supports the hypothesis that FO may alter autonomic 
control. Furthermore, the increased levels of hydration status were associated with higher levels 
of EE’, a marker of LV diastolic dysfunction, at post-HD. Chronic FO has been associated with 
pathological myocardial dilation, and our results add to the evidence for myocardial functional 
impairment in overhydrated HD patients.   
 
 
 
139 
 
7.8 Adverse Events 
In this study, 32.3% of HD sessions were associated with IDH and 16.1% with IDHTP. The 
sessions with IDH were mostly accompanied with physical symptoms, and half of the sessions 
with IDH required saline infusion and/or adjustments to the ultrafiltration volume and/or flow 
rates. No effect of IDEX was found in the presence of IDH and IDHPT, and the history of IDH 
and IDHPT also did not have a significant effect on our main outcomes. As such, no IDEX-
driven serious adverse events were observed throughout the study period. However, two patients 
developed severe hypotensive symptoms (cramping and nausea) accompanied by a rapid drop in 
SBP immediately after performing the 3rd-hr exercise. The symptoms remained until a few hours 
after the HD sessions. It might be argued that the hypotensive symptoms were in part driven by 
the 3rd-hour exercise during HD. However, the first patient with the adverse event had a post-
HD weight on that day that was 1 kg below their prescribed dry weight, suggesting the patient 
may have been under-hydrated. The second patient had an exceptionally high ultrafiltration 
volume (4500ml) considering their body size (152 cm in height and 120kg in body weight) on 
their 3rd hour exercise day. Thus, it is not clear whether the late-hour exercise, excessive 
ultrafiltration, or both, contributed to the development of the hypotensive symptoms. It also 
should be recognized that brachial and aortic BP were lower throughout the 3rd-hour IDEX day 
compared to other intervention days during the mid-hours of HD. Although the reason for this is 
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unclear, the suppressed BP before performing the 3rd-hour IDEX indicates that the last-hour 
exercise was unlikely to be the reason for the hypotensive events. For the sake of maximal 
safety, it should be advised to examine potential factors that may increase the risk of HD-
intolerance such as abnormal hydration status at pre-HD, as well as recent illness, when 
considering IDEX in the 3rd hour of treatment.      
  
7.9 Limitations 
This study has several limitations. First, exercise intensity and workload were not objectively 
measured. Different levels of exercise intensity cause different physiological responses and the 
results from the self-selected intensity exercise may limit the generalizability of the results to all 
HD patients. Similarly, the blunted CV response, as indicted by no significant increases in HR, 
CO and BP, during the 3rd-hour exercise may also be attributed to the subjectivity of exercise 
intensity. Patients may be less motivated to exercise during the last hour than the earlier hours 
during HD sessions due to the HD-driven physical and mental exhaustion. As such, the intensity 
of exercise during the 3rd-hour may have been decreased compared to the levels that patients 
would exercise during 1st-hour into HD. However, we chose this approach (RPE-based) because 
it was the most practical approach, and it is similar to how exercise is normally prescribed in 
IDEX programs in the United States. Furthermore, the gold standard method (HR-based) remain 
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invalid due to the high prevalence of autonomic dysfunction in HD patients. Calibration to 
estimate the total workload was unfortunately not possible with the ergometers used in our study.  
Second, patient’s IDWG and the subsequent ultrafiltration volume were not controlled 
between intervention sessions, although patients were advised to maintain the typical eating 
patterns during the study period. HD patients are recognized to be heterogeneous in their 
hemodynamic response to HD, particularly related to ultrafiltration volumes. Environmental 
factors as well as HD prescriptions should be considered as potential confounding factors for 
hemodynamic changes during HD in future studies. Third, only a subset of patients was available 
for cardiac and arterial measures at pre- and post-HD. Thus, the impact of CV comorbidities on 
the intradialytic hemodynamic responses were not adequately powered to examine as 
confounding factors.  
    
7-10. Conclusion 
 From a public policy perspective, IDEX training represents a low-cost, easy to administer 
treatment strategy that could potentially reduce the burden of CV disease and other uremic 
symptoms in this population. Our data suggests that IDEX does not exacerbate hemodynamic 
instability during HD regardless of hydration status and the timing of the exercise. Despite the 
gradual decreases in brachial and aortic BP throughout HD, IDEX did not cause further 
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hemodynamic instability. We also observed the potential roles of overhydration and autonomic 
dysfunction on hemodynamic regulation during HD. These results should help to improve our 
understanding regarding the CV safety of IDEX. Such understating will lead to improve 
therapeutic approaches, including exercise training, that will prevent or minimize the deleterious 
effect of renal failure, as well as the HD process itself. 
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